<SEC-DOCUMENT>0001193125-25-143665.txt : 20250620
<SEC-HEADER>0001193125-25-143665.hdr.sgml : 20250620
<ACCEPTANCE-DATETIME>20250620161626
ACCESSION NUMBER:		0001193125-25-143665
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250617
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250620
DATE AS OF CHANGE:		20250620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		251061575

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d925162d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20250617" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-06-17_to_2025-06-17">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-353">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-17_to_2025-06-17">0001095981</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="pstv-20250617.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-17_to_2025-06-17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-17</xbrli:startDate> <xbrli:endDate>2025-06-17</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-364">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt:datemonthdayyearen" id="ixv-365">June&#160;17, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-366">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:stateprovnameen" id="ixv-367">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-368">001-34375</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-369">33-0827593</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-370">2710 Reed Road</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-371">Suite 160</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-372">Houston</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:stateprovnameen" id="ixv-373">Texas</ix:nonNumeric>&#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-374">77051</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, with zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-375">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-376">255-7194</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-377">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-378">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-379">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-380">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-381">Common Stock, par value $0.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-382">PSTV</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-383">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;17, 2025, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park has committed to purchase up to $50&#160;million of the Company&#8217;s common stock, $0.001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;Commitment Amount&#8221;). Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s sole discretion, over the <span style="white-space:nowrap">36-month</span> period commencing on the date that a registration statement covering the resale of shares of common stock that have been and may be issued under the Purchase Agreement, which the Company initially filed on June&#160;18, 2025 with the Securities and Exchange Commission (the &#8220;SEC&#8221;) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Purchase Agreement, so long as the closing sale price of the Company&#8217;s common stock is not below $0.10 on a particular business day, the Company may from time to time direct Lincoln Park to purchase up to 300,000 shares of common stock in a regular purchase (the &#8220;Regular Purchase&#8221;) on such business day (such share amount limitation, the &#8220;Regular Purchase Share Limit&#8221;), provided, however, that the Regular Purchase may be increased to up to 400,000 shares if the last closing sale price for the common stock at the time of the sale is not below $0.50 and up to a maximum amount of 500,000 shares of the Company&#8217;s common stock if the last closing sale price for the common stock at the time of sale is not below $0.75. In each case, Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $1,000,000. The Regular Purchase Share Limit is subject to proportionate adjustment in the event of a reorganization, recapitalization, <span style="white-space:nowrap">non-cash</span> dividend, stock split or other similar transaction; provided, that if after giving effect to such full proportionate adjustment, the adjusted Regular Purchase Share Limit would preclude the Company from requiring Lincoln Park to purchase shares of its common stock at an aggregate purchase price equal to or greater than $50,000 in any single Regular Purchase, then the Regular Purchase Share Limit will not be fully adjusted, but rather the Regular Purchase Share Limit for such Regular Purchase shall be adjusted as specified in the Purchase Agreement, such that, after giving effect to such adjustment, the Regular Purchase Share Limit will be equal to (or as close as can be derived from such adjustment without exceeding) $50,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Regular Purchase will be equal to 97% of the lower of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lowest sale price for the Company&#8217;s common stock on the purchase date for such shares of common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the arithmetic average of the three lowest closing sale prices for the Company&#8217;s common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares of the common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Regular Purchases described above, the Company may also direct Lincoln Park, on any business day on which it has properly submitted a Regular Purchase notice directing Lincoln Park to purchase the maximum number of shares of its common stock that it is then permitted to include in a single Regular Purchase notice, to purchase an additional amount of its common stock (an &#8220;Accelerated Purchase&#8221;), not to exceed the lesser of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">30% of the aggregate number of shares of the Company&#8217;s common stock traded during all or, if certain trading volume or market price thresholds specified in the Purchase Agreement are crossed on the next business day following the purchase date for the corresponding Regular Purchase applicable (the &#8220;Accelerated Purchase Date&#8221;), the portion of the normal trading hours on the applicable Accelerated Purchase Date prior to such time that any one of such thresholds is crossed (such period of time, the &#8220;Accelerated Purchase Measurement Period&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">300% of the number of purchase shares purchased pursuant to the corresponding Regular Purchase. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Accelerated Purchase will be equal to 96.5% of the lower of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the volume weighted average price of the Company&#8217;s common stock during the Accelerated Purchase Measurement Period on the applicable Accelerated Purchase Date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the closing sale price of the Company&#8217;s common stock on the applicable Accelerated Purchase Date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may also direct Lincoln Park, not later than 1:00 p.m., Eastern time, on a business day on which an Accelerated Purchase has been completed and all of the shares of its common stock to be purchased thereunder (and under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time on such business day, to purchase (an &#8220;Additional Accelerated Purchase&#8221;) an additional amount of its common stock of up to the lesser of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">30% of the aggregate number of shares of the Company&#8217;s common stock traded during a certain portion of the normal trading hours on such Accelerated Purchase Date as determined in accordance with the Purchase Agreement (the &#8220;Additional Accelerated Purchase Measurement Period&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">300% of the number of purchase shares purchased pursuant to the Regular Purchase corresponding to the Accelerated Purchase that was completed on such Accelerated Purchase Date on which an Additional Accelerated Purchase notice was properly received. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may, in its sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park prior to 1:00 p.m., Eastern time, on a single Accelerated Purchase Date (the &#8220;Additional Accelerated Purchase Date&#8221;), provided that all prior Accelerated Purchases and Additional Accelerated Purchases (including those that have occurred earlier on the same day) have been completed and all of the shares of the Company&#8217;s common stock to be purchased thereunder (and under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Additional Accelerated Purchase will be equal to 96.5% of the lower of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the volume weighted average price of the Company&#8217;s common stock during the applicable Additional Accelerated Purchase Measurement Period on the applicable Additional Accelerated Purchase Date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the closing sale price of the Company&#8217;s common stock on the applicable Additional Accelerated Purchase Date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, <span style="white-space:nowrap">non-cash</span> dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase price. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will need stockholder approval before issuing more than 10,194,593 shares (including any shares issuable to Lincoln Park under the Purchase Agreement in consideration for its commitment to purchase shares of the Company&#8217;s common stock, the &#8220;Exchange Cap&#8221;), which represents 19.99% of its outstanding shares immediately prior to the execution of the Purchase Agreement, unless (i)&#160;the Company obtains stockholder approval to issue shares of its common stock in excess of the Exchange Cap or (ii)&#160;the average price of all applicable sales of its common stock to Lincoln Park under the Purchase Agreement equals or exceeds $0.3576 per share (which represents the sum of (i) $0.3086, representing the lower of (A)&#160;the official closing price of the Company&#8217;s common stock on Nasdaq immediately preceding the execution of the Purchase Agreement and (B)&#160;the average official closing price of its common stock on Nasdaq for the ten consecutive trading days immediately preceding the execution of the Purchase Agreement and (ii) $0.049) so that the Exchange Cap limitation would not apply to issuances and sales of common stock under the Purchase Agreement pursuant to the rules and regulations of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on June&#160;17, 2025, the Company entered into a letter agreement (the &#8220;Side Letter&#8221;) with certain holders of the Company&#8217;s warrants issued on March&#160;4, 2025. Pursuant to the Side Letter, among other things, such holders agreed to return the shares and <span style="white-space:nowrap">pre-funded</span> warrants the Company issued to them on March&#160;4, 2025 and the Company agreed to repay the holders holding such securities 115% of the value of such securities, using 90% of </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the proceeds from any capital raised by the Company subsequent to July&#160;1, 2025 (the &#8220;Make-Whole Repayment&#8221;). The total amount of the repayment is approximately $17.3&#160;million. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park will be used for working capital and general corporate purposes and, if required, Make-Whole Repayment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed with Lincoln Park that it will not enter into any &#8220;equity line of credit&#8221; or &#8220;at the market&#8221; transactions with any third party for a period defined in the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#8217;s shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Lincoln Park&#8217;s commitment to purchase shares of the Company&#8217;s common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, the Company agreed to pay Lincoln Park an initial commitment fee on a date selected by the Company between July&#160;1, 2025 and August&#160;8, 2025 at a value of $500,000 in cash, shares of common stock or any combination thereof. An additional commitment fee of $500,000 will be paid if and when the Company sells over $25.0&#160;million of the Company&#8217;s common stock under the Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or any combination of cash and common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. During any &#8220;event of suspension&#8221; under the Purchase Agreement, Lincoln Park does not have the right to terminate the Purchase Agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of suspension is cured. In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;3.02.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)). The securities referred to in this current report on Form <span style="white-space:nowrap">8-K</span> are being issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section&#160;4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d925162dex101.htm">Purchase Agreement, dated June&#160;18, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d925162dex102.htm">Registration Rights Agreement, dated June&#160;18, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&#160;20, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Marc H. Hedrick, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d925162dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>PURCHASE AGREEMENT </B>(the &#147;<U>Agreement</U>&#148;), dated as of June 17, 2025, by and between <B>PLUS THERAPEUTICS, INC.</B>, a
Delaware corporation (the &#147;<U>Company</U>&#148;), and <B>LINCOLN PARK CAPITAL FUND, LLC</B>, an Illinois limited liability company (the &#147;<U>Investor</U>&#148;). Capitalized terms used herein and not otherwise defined are defined in
<U>Section</U><U></U><U>&nbsp;1</U> of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy
from the Company, up to the then applicable Available Amount of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;). The shares of Common Stock to be purchased by the Investor hereunder are referred to
herein as the &#147;<U>Purchase Shares.</U>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto are entering into a Registration Rights Agreement, dated as of the
date hereof (the &#147;<U>Registration Rights Agreement</U>&#148;), pursuant to which the Company shall register under the Securities Act the resale of the Registrable Securities (as defined in the Registration Rights Agreement) by the Investor upon
the terms and subject to the conditions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants contained in this
Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CERTAIN DEFINITIONS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#147;<U>Accelerated Purchase Date</U>&#148; means, with respect to any Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the Business Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;&#147;<U>Accelerated Purchase Minimum Price Threshold</U>&#148; means, with
respect to any Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the greater of (i)&nbsp;seventy-five percent (75%) of the Closing Sale Price of the Common Stock on the applicable Purchase Date with respect to the
corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof and (ii)&nbsp;the minimum per share price threshold set forth in the applicable Accelerated Purchase Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;&#147;<U>Accelerated Purchase Notice</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to purchase the number of Purchase Shares specified by the Company therein as the Accelerated Purchase Share Amount
to be purchased by the Investor (such specified Accelerated Purchase Share Amount subject to adjustment in accordance with <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof as necessary to give effect to the Purchase Share amount limitations applicable
to such Accelerated Purchase Share Amount as set forth in this Agreement) at the applicable Accelerated Purchase Price on the applicable Accelerated Purchase Date for such Accelerated Purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;&#147;<U>Accelerated Purchase Price</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, <FONT STYLE="white-space:nowrap">ninety-six</FONT> and a half percent (96.5%) of the lower of (i)&nbsp;the VWAP for the period beginning at 9:30:01 a.m., Eastern time, on the applicable Accelerated
Purchase Date, or such other </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time publicly announced by the Principal Market as the official open (or commencement) of trading on the Principal Market on such applicable Accelerated Purchase Date (the &#147;<U>Accelerated
Purchase Commencement Time</U>&#148;), and ending at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading on the
Principal Market on such applicable Accelerated Purchase Date, (B)&nbsp;such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the total number (or volume) of shares of Common Stock traded on the
Principal Market has exceeded the applicable Accelerated Purchase Share Volume Maximum, and (C)&nbsp;such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the Sale Price has fallen below the
applicable Accelerated Purchase Minimum Price Threshold (such earliest of (i)(A), (i)(B) and (i)(C) above, the &#147;<U>Accelerated Purchase Termination Time</U>&#148;), and (ii)&nbsp;the Closing Sale Price of the Common Stock on such applicable
Accelerated Purchase Date (to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;&#147;<U>Accelerated Purchase Share Amount</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor in an Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the
number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof (subject to the Purchase Share limitations contained in <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof) and (ii)&nbsp;an amount equal to (A)&nbsp;the Accelerated Purchase Share Percentage multiplied by
(B)&nbsp;the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Accelerated Purchase Date beginning at the Accelerated Purchase Commencement Time for such Accelerated Purchase and
ending at the Accelerated Purchase Termination Time for such Accelerated Purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;&#147;<U>Accelerated Purchase Share
Percentage</U>&#148; means, with respect to an Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, thirty percent (30%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;&#147;<U>Accelerated Purchase Share Volume Maximum</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, a number of shares of Common Stock equal to (i)&nbsp;the number of Purchase Shares specified by the Company in the applicable Accelerated Purchase Notice as the Accelerated Purchase Share Amount to be
purchased by the Investor in such Accelerated Purchase, divided by (ii)&nbsp;the Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend,
stock split, reverse stock split or other similar transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;&#147;<U>Additional Accelerated Purchase Date</U>&#148; means,
with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the Business Day (i)&nbsp;that is the Accelerated Purchase Date with respect to the corresponding Accelerated Purchase referred to in
clause (i)&nbsp;of the proviso in the second sentence of<U> Section</U><U></U><U>&nbsp;2(c)</U> hereof and (ii)&nbsp;on which the Investor receives, prior to 1:00 p.m., Eastern time, on such Business Day, a valid Additional Accelerated Purchase
Notice for such Additional Accelerated Purchase in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;&#147;<U>Additional Accelerated Purchase
Minimum Price Threshold</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the greater of (i)&nbsp;seventy-five percent (75%) of the Closing Sale Price of the Common
Stock on the Business Day immediately preceding the applicable Additional Accelerated Purchase Date with respect to such Additional Accelerated Purchase and (ii)&nbsp;the minimum per share price threshold set forth in the applicable Additional
Accelerated Purchase Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;&#147;<U>Additional Accelerated Purchase Notice</U>&#148; means, with respect to an Additional
Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to purchase the number of Purchase Shares specified by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company therein as the Additional Accelerated Purchase Share Amount to be purchased by the Investor (such specified Additional Accelerated Purchase Share Amount subject to adjustment in
accordance with <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof as necessary to give effect to the Purchase Share amount limitations applicable to such Additional Accelerated Purchase Share Amount as set forth in this Agreement) at the applicable
Additional Accelerated Purchase Price on the applicable Additional Accelerated Purchase Date for such Additional Accelerated Purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;&#147;<U>Additional Accelerated Purchase Price</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, <FONT STYLE="white-space:nowrap">ninety-six</FONT> and a half percent (96.5%) of the lower of (i)&nbsp;the VWAP for the period on the applicable Additional Accelerated Purchase Date, beginning at the
latest of (A)&nbsp;the applicable Accelerated Purchase Termination Time with respect to the corresponding Accelerated Purchase referred to in clause (i)&nbsp;of the proviso in the second sentence of <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof on
such Additional Accelerated Purchase Date, (B)&nbsp;the applicable Additional Accelerated Purchase Termination Time with respect to the most recently completed prior Additional Accelerated Purchase on such Additional Accelerated Purchase Date, as
applicable, and (C)&nbsp;the time at which all Purchase Shares subject to all prior Accelerated Purchases and Additional Accelerated Purchases (as applicable), including, without limitation, those that have been effected on the same Business Day as
the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement (such latest of (i)(A),
(i)(B) and (i)(C) above, the &#147;<U>Additional Accelerated Purchase Commencement Time</U>&#148;), and ending at the earliest of (X) 4:00 p.m., Eastern time, on such Additional Accelerated Purchase Date, or such other time publicly announced by the
Principal Market as the official close of trading on the Principal Market on such Additional Accelerated Purchase Date, (Y)&nbsp;such time, from and after the Additional Accelerated Purchase Commencement Time for such Additional Accelerated
Purchase, that the total number (or volume) of shares of Common Stock traded on the Principal Market has exceeded the applicable Additional Accelerated Purchase Share Volume Maximum, and (Z)&nbsp;such time, from and after the Additional Accelerated
Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale Price has fallen below the applicable Additional Accelerated Purchase Minimum Price Threshold (such earliest of (i)(X), (i)(Y) and (i)(Z) above, the
&#147;<U>Additional Accelerated Purchase Termination Time</U>&#148;), and (ii)&nbsp;the Closing Sale Price of the Common Stock on such Additional Accelerated Purchase Date (to be appropriately adjusted for any reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;&#147;<U>Additional Accelerated Purchase Share Amount</U>&#148; means, with respect to an Additional Accelerated Purchase made
pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor on an Additional Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the
lesser of (i) 300% of the number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i)&nbsp;of the proviso in
the second sentence of <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof (subject to the Purchase Share limitations contained in <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof) and (ii)&nbsp;an amount equal to (A)&nbsp;the Additional Accelerated Purchase
Share Percentage multiplied by (B)&nbsp;the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Additional Accelerated Purchase Date beginning at the Additional Accelerated Purchase
Commencement Time for such Additional Accelerated Purchase and ending at the Additional Accelerated Purchase Termination Time for such Additional Accelerated Purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;&#147;<U>Additional Accelerated Purchase Share Percentage</U>&#148; means, with respect to an Additional Accelerated Purchase made
pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, thirty percent (30%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;&#147;<U>Additional Accelerated Purchase Share
Volume Maximum</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, a number of shares of Common Stock equal to (i)&nbsp;the number of Purchase Shares specified by the
Company in the applicable Additional Accelerated Purchase Notice as the Additional Accelerated Purchase Share Amount to be purchased by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor in such Additional Accelerated Purchase, divided by (ii)&nbsp;the Additional Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization,
<FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;&#147;<U>Alternate Adjusted Regular Purchase Share Limit</U>&#148; means, with respect to a Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, the maximum number of Purchase Shares which, taking into account the applicable per share Purchase Price therefor calculated in accordance with this Agreement, would enable the Company to deliver to the
Investor, on the applicable Purchase Date for such Regular Purchase, a Regular Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, Fifty Thousand Dollars ($50,000). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#8195;&#147;<U>Available Amount</U>&#148; means, initially, Twenty-Five Million Dollars ($25,000,000) in the aggregate (the
&#147;<U>Initial Available Amount</U>&#148;), which Initial Available Amount shall be reduced by the Purchase Amount each time the Investor purchases Purchase Shares pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof, and, if the full Initial
Available Amount of Purchase Shares in the aggregate shall have been purchased by the Investor pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof prior to the Maturity Date, then, immediately and automatically upon the completion of the purchase
by the Investor of the full Initial Available Amount of Purchase Shares in the aggregate pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof, the &#147;<U>Available Amount</U>&#148; shall mean, at all times from and after the completion of the
Investor&#146;s purchase of the full Initial Available Amount of Purchase Shares in the aggregate pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof until the Maturity Date, Fifty Million Dollars ($50,000,000) in the aggregate (inclusive of the
full Initial Available Amount previously purchased by the Investor), which additional amount of Twenty-Five Million Dollars ($25,000,000) shall be reduced by the Purchase Amount each time the Investor purchases Purchase Shares pursuant to
<U>Section</U><U></U><U>&nbsp;2</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;&#147;<U>Average Price</U>&#148; means a price per Purchase Share (rounded to the
nearest tenth of a cent) equal to the quotient obtained by dividing (i)&nbsp;the aggregate gross purchase price paid by the Investor for all Purchase Shares purchased pursuant to this Agreement, by (ii)&nbsp;the aggregate number of Purchase Shares
issued pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&#8195;&#147;<U>Bankruptcy Law</U>&#148; means Title 11, U.S. Code, or any similar federal or state
law for the relief of debtors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&#8195;&#147;<U>Base Price</U>&#148; means a price per Purchase Share equal to the sum of (i)&nbsp;the
Signing Market Price and (ii) $0.049 (subject to adjustment for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction that occurs on or after
the date of this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&#8195;&#147;<U>Business Day</U>&#148; means any day on which the Principal Market is open for trading,
including any day on which the Principal Market is open for trading for a period of time less than the customary time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&#8195;
&#147;<U>Cash Commitment Fee</U>&#148; means, collectively, the Initial Cash Commitment Fee (as defined in <U>Section</U><U></U><U>&nbsp;5(e)</U> hereof) and the Additional Cash Commitment Fee (as defined in <U>Section</U><U></U><U>&nbsp;5(e)</U>
hereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#8195;&#147;<U>Closing Sale Price</U>&#148; means, for any security as of any date, the last closing sale price for such
security on the Principal Market as reported by the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&#8195;&#147;<U>Commitment Shares</U>&#148; means, collectively,
the Initial Commitment Shares (as defined in <U>Section</U><U></U><U>&nbsp;5(e) </U>hereof) and the Additional Commitment Shares (as defined in <U>Section</U><U></U><U>&nbsp;5(e) </U>hereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&#8195;&#147;<U>Confidential Information</U>&#148; means any information disclosed by
either party to the other party, either directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated as
&#147;Confidential,&#148; &#147;Proprietary&#148; or some similar designation. Information communicated orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten
(10)&nbsp;Business Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i)&nbsp;was
publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii)&nbsp;becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party
through no action or inaction of the receiving party; (iii)&nbsp;is already in the possession of the receiving party without confidential restriction at the time of disclosure by the disclosing party as shown by the receiving party&#146;s files and
records immediately prior to the time of disclosure; (iv)&nbsp;is obtained by the receiving party from a third party without a breach of such third party&#146;s obligations of confidentiality; (v)&nbsp;is independently developed by the receiving
party without use of or reference to the disclosing party&#146;s Confidential Information, as shown by documents and other competent evidence in the receiving party&#146;s possession; or (vi)&nbsp;is required by law to be disclosed by the receiving
party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&#8195;&#147;<U>Custodian</U>&#148; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&#8195;&#147;<U>DTC</U>&#148; means The Depository Trust Company, or any successor performing substantially the same function for the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&#8195;&#147;<U>DWAC Shares</U>&#148; means shares of Common Stock that are (i)&nbsp;issued in electronic form,
(ii)&nbsp;freely tradable and transferable and without restriction on resale and (iii)&nbsp;timely credited by the Company to the Investor&#146;s or its designee&#146;s specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast
Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) &#8195;&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&#8195;&#147;<U>Floor Price</U>&#148; means, with respect to a Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, $0.10, which shall be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction and, effective
upon the consummation of any such reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction, the Floor Price shall mean the <U>lower</U> of (i)&nbsp;the adjusted price and
(ii) $0.50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&#8195;&#147;<U>Fully Adjusted Regular Purchase Share Limit</U>&#148; means, with respect to any reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction from and after the date of this Agreement, the Regular Purchase Share Limit (as defined in <U>Section</U><U></U><U>&nbsp;2(a)
</U>hereof) in effect on the applicable date of determination, after giving effect to the full proportionate adjustment thereto made pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof for or in respect of such reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&#8195;&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on (i)&nbsp;the enforceability of any Transaction
Document, (ii)&nbsp;the results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse effect that resulted exclusively from (A)&nbsp;any change in the United
States or foreign economies or securities or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B)&nbsp;any change that generally affects the industry in which the
Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C)&nbsp;any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war,
sabotage or terrorism or military actions existing as of the date hereof, (D)&nbsp;any action taken by the Investor, its affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E)&nbsp;the
effect of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, or (F)&nbsp;any change resulting from compliance with terms of this Agreement or the
consummation of the transactions contemplated by this Agreement, or (iii)&nbsp;the Company&#146;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document to be performed as of the date of
determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&#8195;&#147;<U>Maturity Date</U>&#148; means the first day of the month immediately following the <FONT
STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month anniversary of the Commencement Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&#8195;&#147;<U>PEA
Period</U>&#148; means the period commencing at 9:30 a.m., Eastern time, on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day immediately prior to the filing of any post-effective amendment to the Registration
Statement (as defined herein) or New Registration Statement (as such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately following, the effective date of any post-effective
amendment to the Registration Statement (as defined herein) or New Registration Statement (as such term is defined in the Registration Rights Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&#8195;&#147;<U>Person</U>&#148; means an individual or entity including but not limited to any limited liability company, a partnership,
a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;&#147;<U>Principal Market</U>&#148; means The Nasdaq Capital Market (or any nationally recognized successor thereto); provided,
however, that in the event the Company&#146;s Common Stock is ever listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or The OTCQX Best Market or The OTCQB
Venture Market operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the &#147;<U>Principal Market</U>&#148; shall mean such other market or exchange on which the Company&#146;s Common Stock is
then listed or traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&#8195;&#147;<U>Purchase Amount</U>&#148; means, with respect to any Regular Purchase, any Accelerated
Purchase or any Additional Accelerated Purchase made hereunder, as applicable, the portion of the Available Amount to be purchased by the Investor pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&#8195;&#147;<U>Purchase Date</U>&#148; means, with respect to a Regular Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>
hereof, the Business Day on which the Investor receives, after 4:00 p.m., Eastern time, but prior to 5:00 p.m., Eastern time, on such Business Day, a valid Regular Purchase Notice for such Regular Purchase in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&#8195;&#147;<U>Purchase Price</U>&#148; means, with respect to any Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, ninety-seven percent (97%) of the lower of: (i)&nbsp;the lowest Sale Price on the applicable Purchase Date for such Regular Purchase and (ii)&nbsp;the arithmetic average of the three (3)&nbsp;lowest
Closing Sale Prices for the Common Stock during the ten (10)&nbsp;consecutive Business Days ending on the Business Day immediately preceding such Purchase Date for such Regular Purchase (in each case, to be appropriately adjusted for any
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction that occurs on or after the date of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&#8195;&#147;<U>Regular Purchase Notice</U>&#148; means, with respect to any Regular Purchase pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the applicable Purchase Price as specified by the Company
therein on the applicable Purchase Date for such Regular Purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&#8195;&#147;<U>Sale Price</U>&#148; means any trade price for the shares of Common
Stock on the Principal Market as reported by the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&#8195;&#147;<U>SEC</U>&#148; means the U.S. Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) &#8195;&#147;<U>Securities</U>&#148; means, collectively, the Purchase Shares and the Commitment Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&#8195;&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) &#8195;&#147;<U>Signing Market Price</U>&#148; means $0.3086, representing the official closing price of the Common
Stock on The Nasdaq Capital Market (as reflected on Nasdaq.com) on the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&#8195;&#147;<U>Subsidiary</U>&#148;
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&#8195;&#147;<U>Transaction Documents</U>&#148; means,
collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement and the schedules and exhibits thereto, and each of the other agreements, documents, certificates and instruments entered into or furnished by the
parties hereto in connection with the transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&#8195;&#147;<U>Transfer Agent</U>&#148; means
Broadridge Corporate Solutions, Inc., or such other Person who is then serving as the transfer agent for the Company in respect of the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&#8195;&#147;<U>VWAP</U>&#148; means in respect of an Accelerated Purchase Date and an Additional Accelerated Purchase Date, as
applicable, the volume weighted average price of the Common Stock on the Principal Market, as reported on the Principal Market or by another reputable source such as Bloomberg, L.P. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURCHASE OF COMMON STOCK. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, in the Company&#146;s sole
and absolute discretion, and the Investor has the obligation to purchase from the Company, Purchase Shares as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Commencement of Regular Sales of Common Stock</U>. Upon the satisfaction of all of the conditions set forth in <U>Sections 7</U>
and <U>8</U> hereof (the &#147;<U>Commencement</U>&#148; and the date of satisfaction of such conditions the &#147;<U>Commencement Date</U>&#148;) and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by
its delivery to the Investor of a Regular Purchase Notice from time to time, to purchase up to Three Hundred Thousand (300,000) Purchase Shares, subject to adjustment as set forth below in this <U>Section</U><U></U><U>&nbsp;2(a)</U> (such maximum
number of Purchase Shares, as may be adjusted from time to time, the &#147;<U>Regular Purchase Share Limit</U>&#148;), at the Purchase Price on the Purchase Date (each such purchase a &#147;<U>Regular Purchase</U>&#148;); <U>provided</U>,
<U>however</U>, that (i)&nbsp;the Regular Purchase Share Limit shall be increased to up to Four Hundred Thousand (400,000) Purchase Shares, if the Closing Sale Price of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock on the applicable Purchase Date is not below $0.50, and (ii)&nbsp;the Regular Purchase Share Limit shall be increased to up to Five Hundred Thousand (500,000) Purchase Shares, if the
Closing Sale Price of the Common Stock on the applicable Purchase Date is not below $0.75 (all of which share and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization,
<FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction; <U>provided</U> that if, after giving effect to the full proportionate adjustment to the Regular Purchase Share Limit therefor, the Fully Adjusted
Regular Purchase Share Limit then in effect would preclude the Company from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase Amount (calculated by multiplying (X)&nbsp;the number of Purchase Shares equal to the Fully
Adjusted Regular Purchase Share Limit, by (Y)&nbsp;the Purchase Price per Purchase Share covered by such Regular Purchase Notice on the applicable Purchase Date therefor) equal to or greater than Fifty Thousand Dollars ($50,000), the Regular
Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the applicable Fully Adjusted Regular Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular Purchase Notice shall be adjusted to
equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase Date for such Regular Purchase Notice); and <U>provided</U>, <U>further</U>, <U>however</U>, that the Investor&#146;s committed obligation under any
single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted Regular Purchase Share Limit shall apply, shall not exceed One Million Dollars ($1,000,000). If the Company delivers any Regular Purchase Notice for
a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void <I>ab initio </I>to the extent of the amount by which the number of Purchase Shares set forth in such Regular
Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such
Regular Purchase Notice; <U>provided</U>, <U>however</U>, that the Investor shall remain obligated to purchase the number of Purchase Shares which the Company is permitted to include in such Regular Purchase Notice. The Company may deliver a Regular
Purchase Notice to the Investor as often as every Business Day, so long as (i)&nbsp;the Closing Sale Price of the Common Stock on such Business Day is not less than the Floor Price, (ii)&nbsp;all Purchase Shares subject to all prior Regular
Purchases, Accelerated Purchases and Additional Accelerated Purchases initiated by the Company pursuant to this Agreement, as applicable, have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement, and
(iii)&nbsp;the entire Initial Commitment Fee (including the entire Initial Cash Commitment Fee and all Initial Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Initial Commitment Fee pursuant to
<U>Section</U><U></U><U>&nbsp;5(e)(1)</U>) shall have been received by the Investor, to the extent required to have been received by the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(1)</U> at or prior to the time of delivery of such Regular
Purchase Notice to the Investor, and the entire Additional Commitment Fee (including the entire Additional Cash Commitment Fee and all Additional Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Additional
Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(2)</U>) shall have been received by the Investor, to the extent required to have been received by the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(2)</U> at or prior to the time of
delivery of such Regular Purchase Notice to the Investor. Notwithstanding the foregoing, the Company shall not deliver any Regular Purchase Notices to the Investor during the PEA Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in
addition to purchases of Purchase Shares as described in <U>Section</U><U></U><U>&nbsp;2(a)</U> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated Purchase
Notice from time to time in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price on the Accelerated Purchase Date therefor in accordance with this Agreement (each such
purchase, an &#147;<U>Accelerated Purchase</U>&#148;). The Company may deliver an Accelerated Purchase Notice to the Investor only (i)&nbsp;on a Purchase Date on which the Company also properly submitted a Regular Purchase Notice providing for a
Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then in effect on such Purchase Date in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the
Regular Purchase Share Limit as a result of the Closing Sale Price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Common Stock exceeding certain thresholds set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U> above on such Purchase Date and any other adjustments to the Regular Purchase Share Limit, in
each case pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> above), (ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases initiated by the Company pursuant to this Agreement,
as applicable, have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement, and (iii)&nbsp;the entire Initial Commitment Fee (including the entire Initial Cash Commitment Fee and all Initial Commitment Shares, as
applicable, to be paid or issued in payment of all or any part of the Initial Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(1)</U>) shall have been received by the Investor, to the extent required to have been received by the
Investor under <U>Section</U><U></U><U>&nbsp;5(e)(1)</U> at or prior to the time of delivery of such Accelerated Purchase Notice to the Investor, and the entire Additional Commitment Fee (including the entire Additional Cash Commitment Fee and all
Additional Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Additional Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(2)</U>) shall have been received by the Investor, to the extent required
to have been received by the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(2)</U> at or prior to the time of delivery of such Accelerated Purchase Notice to the Investor. If the Company delivers any Accelerated Purchase Notice directing the
Investor to purchase an amount of Purchase Shares that exceeds the Accelerated Purchase Share Amount that the Company is then permitted to include in such Accelerated Purchase Notice, such Accelerated Purchase Notice shall be void <I>ab initio
</I>to the extent of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase Notice exceeds the Accelerated Purchase Share Amount that the Company is then permitted to include in such Accelerated Purchase Notice
(which shall be confirmed in an Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Accelerated Purchase Notice; <U>provided</U>, <U>however</U>, that the Investor
shall remain obligated to purchase the Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated Purchase Notice. Within one (1)&nbsp;Business Day after completion of each Accelerated Purchase Date for an
Accelerated Purchase, the Investor will provide to the Company a written confirmation of such Accelerated Purchase setting forth the applicable Accelerated Purchase Share Amount and Accelerated Purchase Price for such Accelerated Purchase (each, an
&#147;<U>Accelerated Purchase Confirmation</U>&#148;). Notwithstanding the foregoing, the Company shall not deliver any Accelerated Purchase Notices to the Investor during the PEA Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Additional Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, from and after the Commencement
Date, in addition to purchases of Purchase Shares as described in <U>Section</U><U>&nbsp;2(a)</U> and <U>Section</U><U></U><U>&nbsp;2(b)</U> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its timely
delivery to the Investor of an Additional Accelerated Purchase Notice on an Additional Accelerated Purchase Date in accordance with this Agreement, to purchase the applicable Additional Accelerated Purchase Share Amount at the applicable Additional
Accelerated Purchase Price therefor in accordance with this Agreement (each such purchase, an &#147;<U>Additional Accelerated Purchase</U>&#148;). The Company may deliver multiple Additional Accelerated Purchase Notices to the Investor on an
Additional Accelerated Purchase Date; <U>provided</U>, <U>however</U>, that the Company may deliver an Additional Accelerated Purchase Notice to the Investor only (i)&nbsp;on a Business Day that is also the Accelerated Purchase Date for an
Accelerated Purchase with respect to which the Company properly submitted to the Investor an Accelerated Purchase Notice in accordance with this Agreement on the applicable Purchase Date for a Regular Purchase of a number of Purchase Shares not less
than the Regular Purchase Share Limit then in effect in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale Price of the Common
Stock exceeding certain thresholds set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U> above on such Purchase Date and any other adjustments to the Regular Purchase Share Limit, in each case pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> above),
(ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable Additional
Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, in each case have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement, and (iii)&nbsp;the entire Initial
Commitment Fee (including the entire Initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cash Commitment Fee and all Initial Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Initial Commitment Fee pursuant to
<U>Section</U><U></U><U>&nbsp;5(e)(1)</U>) shall have been received by the Investor, to the extent required to have been received by the Investor under <U><BR>Section</U><U></U><U>&nbsp;5(e)(1)</U> at or prior to the time of delivery of such
Additional Accelerated Purchase Notice to the Investor, and the entire Additional Commitment Fee (including the entire Additional Cash Commitment Fee and all Additional Commitment Shares, as applicable, to be paid or issued in payment of all or any
part of the Additional Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(2)</U>) shall have been received by the Investor, to the extent required to have been received by the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(2)</U> at or
prior to the time of delivery of such Additional Accelerated Purchase Notice to the Investor. If the Company delivers any Additional Accelerated Purchase Notice directing the Investor to purchase an amount of Purchase Shares that exceeds the
Additional Accelerated Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated Purchase Notice, such Additional Accelerated Purchase Notice shall be void <I>ab initio </I>to the extent of the amount by
which the number of Purchase Shares set forth in such Additional Accelerated Purchase Notice exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated Purchase Notice (which
shall be confirmed in an Additional Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Additional Accelerated Purchase Notice; <U>provided</U>, <U>however</U>,
that the Investor shall remain obligated to purchase the Additional Accelerated Purchase Share Amount which the Company is permitted to include in such Additional Accelerated Purchase Notice. Within one (1)&nbsp;Business Day after completion of each
Additional Accelerated Purchase Date, the Investor will provide to the Company a written confirmation of each Additional Accelerated Purchase on such Additional Accelerated Purchase Date setting forth the applicable Additional Accelerated Purchase
Share Amount and Additional Accelerated Purchase Price for each such Additional Accelerated Purchase on such Additional Accelerated Purchase Date (each, an &#147;<U>Additional Accelerated Purchase Confirmation</U>&#148;). Notwithstanding the
foregoing, the Company shall not deliver any Additional Accelerated Purchase Notices to the Investor during the PEA Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>
Payment for Purchase Shares.</U> For each Regular Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Regular Purchase as full payment for such Purchase Shares via wire transfer of immediately
available funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m.,
Eastern time, the next Business Day. For each Accelerated Purchase and each Additional Accelerated Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Accelerated Purchase and Additional
Accelerated Purchase, respectively, as full payment for such Purchase Shares via wire transfer of immediately available funds on the second Business Day following the date that the Investor receives such Purchase Shares. If the Company or the
Transfer Agent shall fail for any reason or for no reason to electronically transfer any Purchase Shares as DWAC Shares in respect of a Regular Purchase, an Accelerated Purchase or an Additional Accelerated Purchase (as applicable) within two
(2)&nbsp;Business Days following the receipt by the Company of the Purchase Price, Accelerated Purchase Price and Additional Accelerated Purchase Price, respectively, therefor in compliance with this <U>Section</U><U></U><U>&nbsp;2(d)</U>, and if on
or after such Business Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of such Purchase Shares that the Investor anticipated receiving from the
Company in respect of such Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase (as applicable), then the Company shall, within two (2)&nbsp;Business Days after the Investor&#146;s request, either (i)&nbsp;pay cash to the
Investor in an amount equal to the Investor&#146;s total purchase price (including customary brokerage commissions, if any) for the shares of Common Stock so purchased (the &#147;<U>Cover Price</U>&#148;), at which point the Company&#146;s
obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii)&nbsp;promptly honor its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if
any) of the Cover Price over the total Purchase Amount paid by the Investor pursuant to this Agreement for all of the Purchase Shares to be purchased by the Investor in connection with such Regular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase, Accelerated Purchase and Additional Accelerated Purchase (as applicable). The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase, Accelerated
Purchase or Additional Accelerated Purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share. All payments
made under this Agreement shall be made in lawful currency of the United States of America by wire transfer of immediately available funds to such account as the Company (or the Investor, as applicable) may from time to time designate by written
notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is a
Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Compliance with Rules of Principal Market</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Exchange Cap</U>. Subject to <U>Section</U><U></U><U>&nbsp;2(e)(ii)</U> below, the Company shall not issue or sell any shares of
Common Stock pursuant to this Agreement, and the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would
be issued pursuant to this Agreement and the transactions contemplated hereby would exceed 10,194,593 (such number of shares equal to 19.99% of the shares of Common Stock issued and outstanding immediately prior to the execution of this Agreement),
which number of shares shall be (i)&nbsp;reduced, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-for-share</FONT></FONT> basis, by the number of shares of Common Stock issued or issuable pursuant to any transaction or
series of transactions that may be aggregated with the transactions contemplated by this Agreement under applicable rules of The Nasdaq Stock Market and (ii)&nbsp;appropriately adjusted for any reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction that occurs after the date of this Agreement (such maximum number of shares, the &#147;<U>Exchange Cap</U>&#148;), unless and until the Company elects to
solicit stockholder approval of the issuance of Common Stock as contemplated by this Agreement, and the stockholders of the Company have in fact approved the issuance of Common Stock as contemplated by this Agreement in accordance with the
applicable rules of The Nasdaq Stock Market. For the avoidance of doubt, the Company may, but shall be under no obligation to, request its stockholders to approve the issuance of Common Stock as contemplated by this Agreement; provided, that if
stockholder approval is not obtained in accordance with this <U>Section</U><U></U><U>&nbsp;2(e)(i)</U>, the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the term of
this Agreement (except as set forth in <U>Section</U><U></U><U>&nbsp;2(e)(ii)</U> below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<U><FONT STYLE="white-space:nowrap">At-Market</FONT> Transaction</U>. Notwithstanding <U>Section</U><U></U><U>&nbsp;2(e)(i)</U>
above, the Exchange Cap shall not be applicable for any purposes of this Agreement and the transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed the Base Price (it being hereby
acknowledged and agreed that the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all other times during the term of this Agreement, unless the stockholder approval referred to in
<U>Section</U><U></U><U>&nbsp;2(e)(i)</U> is obtained). The parties acknowledge and agree that the Signing Market Price used to determine the Base Price hereunder represents the lower of (i)&nbsp;the official closing price of the Common Stock on The
Nasdaq Capital Market (as reflected on Nasdaq.com) on the date of this Agreement and (ii)&nbsp;the average official closing price of the Common Stock on The Nasdaq Capital Market (as reflected on Nasdaq.com) for the five (5)&nbsp;consecutive trading
days ending on the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<U>General</U>. The Company shall not issue any shares of Common Stock pursuant
to this Agreement if such issuance would reasonably be expected to result in (A)&nbsp;a violation of the Securities Act or (B)&nbsp;a breach of the rules and regulations of the Principal Market. The provisions of this
<U>Section</U><U></U><U>&nbsp;2(e)</U> shall be implemented in a manner otherwise than in strict conformity with the terms hereof only if necessary to ensure compliance with the Securities Act, the rules and regulations of the Principal Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>Beneficial Ownership Limitation.</U> Notwithstanding anything to the contrary contained in this Agreement, the Company shall not
issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated
pursuant to Section&nbsp;13(d) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the beneficial ownership by the Investor of more than 4.99% of the then issued and outstanding shares
of Common Stock (the &#147;<U>Beneficial Ownership Limitation</U>&#148;). Upon the written or oral request of the Investor, the Company shall promptly (but not later than 24 hours) confirm orally or in writing to the Investor the number of shares of
Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor&#146;s written certification to the Company of the applicability of the
Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INVESTOR&#146;S REPRESENTATIONS AND WARRANTIES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Organization and Authority</U>. The Investor is an entity duly organized, validly existing and in good standing under the laws of
the jurisdiction of its organization, with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Investment Purpose</U>. The Investor is acquiring the Securities as principal for its own account and not with a view to or for
distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any
applicable state securities law and has no direct or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting the Investor&#146;s right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in compliance with applicable federal and state securities laws).
The Investor is acquiring the Securities hereunder in the ordinary course of its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Accredited Investor Status</U>.
The Investor is an &#147;accredited investor&#148; as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Reliance on Exemptions</U>. The Investor understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor&#146;s compliance with, the representations, warranties,
agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Information</U>. The Investor understands that its investment in the Securities involves a high degree of risk. The Investor
(i)&nbsp;is able to bear the economic risk of an investment in the Securities including a total loss thereof, (ii)&nbsp;has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the
proposed investment in the Securities and (iii)&nbsp;has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial condition and business of the Company and other matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations conducted by the
Investor or its representatives shall modify, amend or affect the Investor&#146;s right to rely on the Company&#146;s representations and warranties contained in <U>Section</U><U></U><U>&nbsp;4</U> below. The Investor has sought such accounting,
legal and tax advice from its own independent advisors as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities and is not relying on any accounting, legal, tax or other advice from the
Company or its officers, employees, representatives or advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>No Governmental Review</U>. The Investor understands that
no U.S. federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of an investment in the Securities nor have such authorities
passed upon or endorsed the merits of the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<U>Transfer or Sale</U>. The Investor understands that
(i)&nbsp;the Securities may not be offered for sale, sold, assigned or transferred unless (A)&nbsp;registered pursuant to the Securities Act or (B)&nbsp;an exemption exists permitting such Securities to be sold, assigned or transferred without such
registration; (ii)&nbsp;any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule&nbsp;144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the
seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<U>Validity; Enforcement</U>. This Agreement has been duly and validly authorized, executed and delivered on behalf
of the Investor and is a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146; rights and remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Residency</U>. The Investor is a resident of the State of Illinois. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<U>No Short Selling</U>. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has
any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) &#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of
the Common Stock or (ii)&nbsp;hedging transaction, which establishes a net short position with respect to the Common Stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to the Investor that, except as set forth in the disclosure schedules attached hereto, which exceptions
shall be deemed to be a part of the representations and warranties made hereunder, as of the date hereof and as of the Commencement Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Organization and Qualification</U>. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as
currently conducted. Neither the Company nor any of its Subsidiaries is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the
Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. The Company has no Subsidiaries
except as set forth on Exhibit 21 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 filed with the SEC on March&nbsp;31, 2025, as amended by Amendment No.&nbsp;1 on
Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> filed with the SEC on April&nbsp;30, 2025 (as so amended, the &#147;<U>2024 Form <FONT STYLE="white-space:nowrap">10-K</FONT></U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Authorization; Enforcement; Validity</U>. (i)&nbsp;The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement, the Registration Rights Agreement and each of the other Transaction Documents, including, without limitation, to issue the Purchase Shares in accordance with the terms hereof and thereof, and to pay the
Cash Commitment Fee and/or to issue the Commitment Shares (as the case may be) in accordance with the terms hereof and thereof, (ii)&nbsp;the execution and delivery of the Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby, including without limitation, (A)&nbsp;the payment of the Initial Cash Commitment Fee and the reservation for issuance and the issuance of the Initial Commitment Shares, as applicable, to be paid or
issued in payment of all or any part of the Initial Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(1)</U>), (B) the payment of the Additional Cash Commitment Fee and the reservation for issuance and the issuance of the Additional
Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Additional Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(2)</U>), and (C)&nbsp;reservation for issuance and the issuance of the Purchase
Shares issuable under this Agreement, in each case have been duly authorized by the Company&#146;s Board of Directors and no further consent or authorization is required by the Company, its Board of Directors or its stockholders (except as provided
in this Agreement), (iii) each of this Agreement and the Registration Rights Agreement has been, and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv)&nbsp;each of this Agreement
and the Registration Rights Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable against the Company in accordance with
their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of
creditors&#146; rights and remedies. The Board of Directors of the Company has approved the resolutions substantially in the form provided to the Investor prior to the date of this Agreement (the &#147;<U>Signing Resolutions</U>&#148;) to authorize
this Agreement, the Registration Rights Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any respect. The Company has delivered to the
Investor a true and correct copy of minutes of a meeting of the Board of Directors of the Company at which the Signing Resolutions were duly adopted by the Board of Directors or a unanimous written consent adopting the Signing Resolutions executed
by all of the members of the Board of Directors of the Company. Except as set forth in this Agreement, no other approvals or consents of the Company&#146;s Board of Directors, any authorized committee thereof, or stockholders (except as provided in
this Agreement) is necessary under applicable laws and the Company&#146;s Certificate of Incorporation or Bylaws to authorize the execution and delivery of the Transaction Documents or any of the transactions contemplated thereby, including, but not
limited to, the issuance of the Commitment Shares and the issuance of the Purchase Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Capitalization</U>. As of the
date hereof, the authorized capital stock of the Company is set forth in the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2025. Except as disclosed in the SEC Documents (as
defined below), (i) no shares of the Company&#146;s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii)&nbsp;there are no outstanding debt securities,
(iii)&nbsp;except pursuant to equity incentive or stock purchase plans disclosed in the SEC Documents, there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue
additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its
Subsidiaries, (iv)&nbsp;except pursuant to equity incentive or stock purchase plans disclosed in the SEC Documents, there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any
of their securities under the Securities Act (except the Registration Rights Agreement), (v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi)&nbsp;there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii)&nbsp;the Company does not have any stock appreciation rights or &#147;phantom stock&#148; plans or
agreements or any similar plan or agreement. The Company has furnished to the Investor true and correct copies of the Company&#146;s Amended and Restated Certificate of Incorporation, as amended and as in effect on the date hereof (the
&#147;<U>Certificate of</U> <U>Incorporation</U>&#148;), and the Company&#146;s Amended and Restated Bylaws, as amended and as in effect on the date hereof (the &#147;<U>Bylaws</U>&#148;), and summaries of the material terms of all securities
convertible into or exercisable for Common Stock, if any, and copies of any documents containing the material rights of the holders thereof in respect thereto that are not disclosed in the SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Issuance of Securities</U>. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the
Purchase Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all
rights accorded to a holder of Common Stock. Upon issuance in accordance with the terms and conditions of this Agreement (as applicable), the Commitment Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens,
charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. 17,000,000 shares of Common Stock have been duly authorized
and reserved for issuance upon purchase under this Agreement as Purchase Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>No Conflicts</U>. The execution, delivery
and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including without limitation, (i)&nbsp;the payment of the Initial Cash Commitment Fee and the
reservation for issuance and the issuance of the Initial Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Initial Commitment Fee pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(1)</U>), (ii) the payment of
the Additional Cash Commitment Fee and the reservation for issuance and the issuance of the Additional Commitment Shares, as applicable, to be paid or issued in payment of all or any part of the Additional Commitment Fee pursuant to
<U>Section</U><U></U><U>&nbsp;5(e)(2)</U>), and (iii)&nbsp;reservation for issuance and the issuance of the Purchase Shares issuable under this Agreement) will not (i)&nbsp;result in a violation of the Certificate of Incorporation, any Certificate
of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the Bylaws or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal Market applicable to the Company or any of its Subsidiaries) or by which any property or asset of the Company or
any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which could not reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor its Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any Certificate of Designation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferences and Rights of any outstanding series of preferred stock of the Company or Bylaws or their organizational charter or bylaws, respectively. Neither the Company nor any of its
Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its
Subsidiaries, except for possible conflicts, defaults, terminations or amendments that could not reasonably be expected to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act
or applicable state securities laws and the rules and regulations of the Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any
regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except as set forth elsewhere in this
Agreement, all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Except as disclosed in the SEC
Documents, since one year prior to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal Market, other than notices with respect to listing of additional shares of Common Stock and other
routine correspondence. Except as disclosed in the SEC Documents, the Principal Market has not commenced any delisting proceedings against the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>SEC Documents; Financial Statements</U>. Other than the Company&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2025, which was filed with the SEC on May&nbsp;30, 2025, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by
the Company with the SEC under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the twelve months preceding the date hereof (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, being collectively referred to herein as the &#147;<U>SEC Documents</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Documents prior to the expiration
of any such extension. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#147;<U>GAAP</U>&#148;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of
and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. Except as set
forth in the SEC Documents, the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof.<B> </B>The SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<U>Absence of Certain Changes</U>. Except as disclosed in the SEC Documents, since December&nbsp;31, 2024, there has been no
material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries. The Company has not taken any steps, and does not currently expect to take any steps, to seek
protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially
solvent and is generally able to pay its debts as they become due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<U>Absence of Litigation</U>. Except as disclosed in the SEC Documents, there is
no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or
affecting the Company, the Common Stock or any of the Company&#146;s or its Subsidiaries&#146; officers or directors in their capacities as such, which could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Acknowledgment Regarding Investor&#146;s Status</U>. The Company acknowledges and agrees that the Investor is acting solely in
the capacity of arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents in connection with the Transaction
Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor&#146;s purchase of the Securities. The Company further represents to the Investor that the Company&#146;s decision to enter into the Transaction
Documents has been based solely on the independent evaluation by the Company and its representatives and advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<U>No
General Solicitation; No Integrated Offering</U>. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D under the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, nor or any of its affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or
solicited any offers to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or cause this
offering of the Securities to be integrated with prior offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated.
The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<U>Intellectual Property Rights</U>. The Company and its Subsidiaries own or possess (or reasonably believe it can acquire on
reasonable terms) adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as now conducted. None of the Company&#146;s material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights,
inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date of this
Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names,
service marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding being made or
brought against, or to the Company&#146;s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark
registrations, trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<U>Environmental Laws</U>. Except as disclosed in the SEC Documents, the Company and its Subsidiaries (i)&nbsp;are in compliance
with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<U>Environmental
Laws</U>&#148;), (ii) have received all permits, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such
permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<U>Title</U>. Neither the Company nor any of its Subsidiaries own any real property. Except as set forth in the SEC Documents, the
Company and its Subsidiaries have good and marketable title in personal property owned by them (other than intellectual property, as discussed in <U>Section</U><U></U><U>&nbsp;4(k)</U> above) that is material to the business of the Company and its
Subsidiaries, in each case free and clear of all liens, encumbrances and defects (&#147;<U>Liens</U>&#148;) and, except for Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed
to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the
Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the use made and proposed
to be made of such property and buildings by the Company and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<U>Insurance</U>. The Company and each of its
Subsidiaries maintain insurance from nationally recognized, in the applicable country, insurers in such amounts and covering such risks as is commercially reasonable in accordance with customary practices for companies engaged in similar businesses
and similar industries for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. All policies of insurance of the Company and
its Subsidiaries are in full force and effect; the Company and each of its Subsidiaries are in compliance with the terms of such policies in all material respects; and neither the Company nor any of its Subsidiaries has received notice from any
insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance; there are no material claims by the Company or any of its Subsidiaries under any such policy
or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;<U>Regulatory Permits</U>. Except as set forth in the SEC Documents, the Company and each of its Subsidiaries have such permits,
licenses, patents, franchises, certificates of need and other approvals consents and other authorizations (the &#147;<U>Regulatory Permits</U>&#148;) issued by the appropriate domestic or foreign regional, federal, state, or local regulatory
agencies or bodies necessary to conduct the business of the Company, including, without limitation, any Regulatory Permits required by the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) or any other authorizations issued by domestic
or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of products such as those being developed by the Company and its Subsidiaries, except for any of the foregoing that would not reasonably be expected to,
individually or in the aggregate, have a Material Adverse Effect; the Company (i)&nbsp;is in compliance in all material respects with the requirements of the Regulatory Permits, and (ii)&nbsp;all of the Regulatory Permits are valid and in full force
and effect, in each case, except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect; the Company has not received any written notice of proceedings relating to the
revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material
Adverse Effect; the Company has not failed to submit to the FDA any applications or other filings necessary to conduct the business of the Company, any such filings that were required to be made were in material compliance with applicable laws when
filed, and no material deficiencies have been asserted by the FDA with respect to any such filings or submissions that were made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;<U>Tax Status</U>. Except as disclosed in the SEC Documents, the Company and each
of its Subsidiaries has made or filed all federal and state income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its
Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be
due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports
or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;<U>Transactions With Affiliates</U>. Except as set forth in the SEC Documents, none of the officers or directors of the Company and,
to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company,
any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services
rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any stock option plan of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&#8195;<U>Application of Takeover Protections</U>. The Company and its board of directors have taken or will take prior to the Commencement
Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate
of Incorporation or the laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&#146;s issuance of the
Securities and the Investor&#146;s ownership of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&#8195;<U>Disclosure</U>. Except with respect to the material terms
and conditions of the transactions contemplated by the Transaction Documents that will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its
agents or counsel with any information that it believes constitutes or might constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the Registration Statement or the SEC Documents. The
Company understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the
Company, its business and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not
misleading. The Company acknowledges and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in
<U>Section</U><U></U><U>&nbsp;3</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&#8195;<U>Foreign Corrupt Practices</U>. Neither the Company nor any of its Subsidiaries,
nor, to the knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its Subsidiaries, has (i)&nbsp;used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of
any provision of the U.S. Foreign Corrupt Practices Act of 1977, the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development Convention on Bribery of Foreign Public Officials in International Business
Transactions, and the rules and regulations thereunder and any other similar foreign or domestic law or regulation; or (iv)&nbsp;made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment. The Company has instituted and
maintains policies and procedures designed to ensure continued compliance with the laws and regulations referenced in clause (iii)&nbsp;of this paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&#8195;<U>DTC Eligibility</U>. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities
Transfer (FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#8195;<U>Sarbanes-Oxley</U>. The Company is in compliance in all material respects with all provisions of the Sarbanes-Oxley Act of 2002,
as amended, which are applicable to it as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&#8195;<U>Certain Fees</U>. No brokerage or finder&#146;s fees or
commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The
Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this <U>Section</U><U></U><U>&nbsp;4(w)</U> that may be due in connection with the
transactions contemplated by the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&#8195;<U>Investment Company</U>. The Company is not, and immediately after
receipt of payment for the Securities will not be, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&#8195;<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is
currently contemplating terminating such registration. Except as disclosed in the SEC Documents, the Company has not, in the twelve (12)&nbsp;months preceding the date hereof, received any notice from any Person to the effect that the Company is not
in compliance with the listing or maintenance requirements of the Principal Market. Except as disclosed in the SEC Documents, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with
all such listing and maintenance requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&#8195;<U>Accountants</U>. BDO USA, P.C., who have certified certain financial
statements of the Company and its consolidated Subsidiaries, whose report appears in the 2024 Form <FONT STYLE="white-space:nowrap">10-K,</FONT> are independent public accountants as required by the Securities Act and the Public Accounting Oversight
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&#8195;<U>No Market Manipulation</U>. The Company has not, and to its knowledge no Person acting on its behalf has,
(i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for,
purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&#8195;<U>Shell Company Status</U>. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the
Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&#8195;<U>Clinical Data and Regulatory Compliance</U>. The clinical and preclinical
studies and tests conducted by the Company and its Subsidiaries and, to the knowledge of the Company, the clinical and preclinical studies conducted on behalf of or sponsored by the Company or its Subsidiaries, were, and if still pending, are, being
conducted in all material respects in accordance with all Applicable Laws, including, but not limited to, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 812. Any descriptions
of clinical, preclinical and other studies and tests, including any related results and regulatory status, contained in the SEC Documents are complete, accurate, and fairly represented in all material respects. Except as disclosed in the SEC
Documents and to the Company&#146;s knowledge, there are no studies, tests or trials the result of which the Company believes reasonably call into question in any material respect the clinical trial results described or referred to in the SEC
Documents when viewed in the context in which such results are described and the clinical state of development. No marketing authorization, including any 510(k) clearance held by the Company, has been terminated or suspended by the FDA, and neither
the FDA nor any applicable foreign regulatory agency has commenced, or, to the Company&#146;s knowledge, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing clinical
investigation conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&#8195;<U>Office of
Foreign Assets Control</U>. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is currently subject to any U.S.
sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<U>OFAC</U>&#148;); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make
available such proceeds to any joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&#8195;<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and
any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<U>Money Laundering Laws</U>&#148;) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&#8195;<U>No Labor Dispute</U>. No labor disturbance by or dispute with the employees of the Company or any of its Subsidiaries exists or,
to the knowledge of the Company, is imminent that could reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&#8195;<U>No
Immunity</U>. Neither the Company nor any Subsidiary, nor any of their respective properties or assets, has any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment to prior judgment,
attachment in aid of execution or otherwise) under the laws of any jurisdiction in which it is organized, headquartered or doing business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&#8195;<U>Information Technology</U>. The Company&#146;s and the Subsidiaries&#146; information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<U>IT Systems</U>&#148;) operate and perform in all material respects as required in connection with the operation of the business of the
Company and the Subsidiaries as currently conducted. The Company, and the Subsidiaries maintain commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity,
continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable, sensitive, confidential or regulated data (&#147;<U>Personal Data</U>&#148;) processed and stored thereon, and to the knowledge of the
Company, there have been no breaches, incidents, violations, outages, compromises or unauthorized uses of or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations
relating to the same. The Company and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or
modification, except for any such noncompliance that would not have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&#8195;<U>No Disqualification
Events</U>. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the
Company&#146;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an
&#147;<U>Issuer Covered Person</U>&#148;) is subject to any of the &#147;Bad Actor&#148; disqualifications described in Rule&nbsp;506(d)(1)(i) to (viii)&nbsp;under the Securities Act (a &#147;<U>Disqualification Event</U>&#148;), except for a
Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COVENANTS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Filing of Current Report and Registration Statement</U>. The Company agrees that it shall, within the time required under the
Exchange Act, file with the SEC a report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents (the &#147;<U>Current
Report</U>&#148;). The Company shall also file with the SEC, within ten (10) Business Days from the date hereof, a new registration statement (the &#147;Registration Statement&#148;) covering only the resale of the Purchase Shares and all of the
Initial Commitment Shares, in accordance with the terms of the Registration Rights. The Company shall permit the Investor to review and comment upon the final <FONT STYLE="white-space:nowrap">pre-filing</FONT> draft version of the Current Report at
least two&nbsp;(2)&nbsp;Business Days prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable best efforts to comment upon the final
<FONT STYLE="white-space:nowrap">pre-filing</FONT> draft version of the Current Report within one (1)&nbsp;Business Day from the date the Investor receives it from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Blue Sky</U>. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or
to register or qualify (i)&nbsp;the issuance of the Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement and (ii)&nbsp;any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in
each case, under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence of any such action so taken to the
Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Listing/DTC</U>. The Company shall promptly secure the listing of all of the Purchase Shares and Commitment Shares
(as applicable) to be issued to the Investor hereunder on the Principal Market (subject to official notice of issuance) and upon each other national securities exchange or automated quotation system, if any, upon which the Common Stock is then
listed, and shall use commercially reasonable efforts to maintain, so long as any shares of Common Stock shall be so listed, such listing of all such Securities from time to time issuable hereunder. The Company shall use commercially reasonable
efforts to maintain the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company&#146;s reporting, filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither
the Company nor any of its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event later than the
following Business Day, provide to the Investor copies of any notices it receives from any Person regarding the continued eligibility of the Common Stock for listing on the Principal Market; provided, however, that the Company shall not be required
to provide the Investor copies of any such notice that the Company reasonably believes constitutes material <FONT STYLE="white-space:nowrap">non-public</FONT> information and the Company would not be required to publicly disclose such notice in any
report or statement filed with the SEC and under the Exchange Act or the Securities Act. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall pay all fees and expenses in connection with satisfying its obligations under this <U>Section</U><U></U><U>&nbsp;5(c)</U>. The Company shall take all action necessary to ensure that
its Common Stock can be transferred electronically as DWAC Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Prohibition of Short Sales and Hedging Transactions</U>.
The Investor agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as provided in Section&nbsp;11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever
enter into or effect, directly or indirectly, any (i) &#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii)&nbsp;hedging transaction, which establishes a net short position
with respect to the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Payment</U><U> </U><U>of</U><U> Initial Commitment </U><U>Fee and Additional
Commitment</U><U> Fee</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Initial Commitment Fee</U>. In consideration for the
Investor&#146;s execution and delivery of this Agreement, at any time after June&nbsp;30, 2025 selected by the Company but in no case after August&nbsp;8, 2025 (such date, the &#147;<U>Initial Commitment Fee Trigger Date</U>&#148;), the Company
shall either (A)&nbsp;pay to the Investor, by wire transfer of immediately available funds to an account designated by the Investor, an amount in cash equal to $500,000, (B) cause to be issued to the Investor a number of shares of Common Stock that
collectively have a total value equal to $500,000 (such number of shares calculated as set forth below), or (C)&nbsp;pay to the Investor (by wire transfer of immediately available funds to an account designated by the Investor) and cause to be
issued to the Investor a combination of an amount in cash and a number of shares of Common Stock (such number of shares calculated as set forth below) that collectively have a combined total value equal to $500,000 (the &#147;<U>Initial Commitment
Fee</U>&#148; and any cash amount that is paid by the Company to the Investor as part of the Initial Commitment Fee pursuant hereto, the &#147;<U>Initial Cash Commitment Fee</U>&#148; and any shares of Common Stock issued by the Company to the
Investor as part of the Initial Commitment Fee pursuant hereto, the &#147;<U>Initial Commitment Shares</U>&#148;). If any Initial Commitment Shares are to be issued hereunder, such Initial Commitment Shares (I)&nbsp;shall have a per share value
equal to the lower of (a) $0.31<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> and (b)&nbsp;such dollar amount equal to ninety-seven percent (97%) of the lower of (1)&nbsp;the lowest Sale Price on the Initial Commitment Fee Trigger Date and
(2)&nbsp;the arithmetic average of the three (3)&nbsp;lowest Closing Sale Prices for the Common Stock during the ten (10)&nbsp;consecutive Business Days ending on the Business Day immediately preceding Initial Commitment Fee Trigger Date (in each
case, to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction that occurs on or after the date of this Agreement), (II) shall be
included in a Registration Statement to be filed by the Company with and declared effective by the SEC pursuant to this Agreement and the Registration Rights Agreement on or prior to the Initial Commitment Fee Trigger Date registering under the
Securities Act the resale by the Investor of such Initial Commitment Shares that may be issued to the Investor hereunder (it being hereby acknowledged and agreed that (x)&nbsp;no shares of Common Stock may be issued to the Investor as Initial
Commitment Shares hereunder if such shares are not included in a Registration Statement (and designated therein as Initial Commitment Shares that may be issued to the Investor pursuant to this Agreement) that is filed by the Company with and
declared effective by the SEC on or before the Initial Commitment Fee Trigger Date and (y)&nbsp;to the extent any portion of the Initial Commitment Fee is not paid to the Investor by the issuance of Initial Commitment Shares (valued in accordance
with clause (I)&nbsp;above) pursuant to and in accordance with this <U>Section</U><U></U><U>&nbsp;5(e)(1)</U>, the full remaining balance of the Initial Commitment Fee payable to the Investor hereunder shall be paid by the Company to the Investor in
cash as the Initial Cash Commitment Fee (at such time and in the manner set forth herein), and (III)&nbsp;shall be received by the Investor as DWAC Shares not later than 10:00 a.m. (New York City time) on the Business Day next following the Initial
Commitment Fee Trigger Date. On the Initial Commitment Fee Trigger Date, if any Initial Commitment Shares are to be issued </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such amount representing the average of the Closing Sale Prices of the Common Stock for the 10 consecutive
Business Days ending on the Business Day immediately prior to June&nbsp;3, 2025 (the date of the Term Sheet). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman">
hereunder, the Company shall deliver to the Transfer Agent the Irrevocable Transfer Agent Instructions with respect to the issuance of such number of Initial Commitment Shares that are to be
issued hereunder. For the avoidance of doubt, the entire Initial Commitment Fee shall be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares are purchased by the Investor under this
Agreement and irrespective of any subsequent termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<U>Additional
Commitment Fee</U>. Not later than 4:00 p.m. (New York City time) on the trading day on which the Company shall have received from the Investor total aggregate cash proceeds equal to $25,000,000 as payment for all shares purchased by the Investor in
all Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases effected pursuant to this Agreement (the &#147;<U>Additional Commitment Fee Trigger Date</U>&#148;), the Company shall either (A)&nbsp;pay to the Investor, by wire
transfer of immediately available funds to an account designated by the Investor, an amount in cash equal to $500,000, (B) cause to be issued to the Investor a number of shares of Common Stock that collectively have a total value equal to $500,000
(such number of shares calculated as set forth below), or (C)&nbsp;pay to the Investor (by wire transfer of immediately available funds to an account designated by the Investor) and cause to be issued to the Investor a combination of an amount in
cash and a number of shares of Common Stock (such number of shares calculated as set forth below) that collectively have a combined total value equal to $500,000 (the &#147;<U>Additional Commitment Fee</U>&#148; and any cash amount that is paid by
the Company to the Investor as part of the Additional Commitment Fee pursuant hereto, the &#147;<U>Additional Cash Commitment Fee</U>&#148; and any shares of Common Stock issued by the Company to the Investor as part of the Additional Commitment Fee
pursuant hereto, the &#147;<U>Additional Commitment Shares</U>&#148;). If any Additional Commitment Shares are to be issued hereunder, such Additional Commitment Shares shall (I)&nbsp;have a per share value equal to ninety-seven percent (97%) of the
lower of (a)&nbsp;the lowest Sale Price on the Additional Commitment Fee Trigger Date and (b)&nbsp;the arithmetic average of the three (3)&nbsp;lowest Closing Sale Prices for the Common Stock during the ten (10)&nbsp;consecutive Business Days ending
on the Business Day immediately preceding Additional Commitment Fee Trigger Date (in each case, to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other
similar transaction that occurs on or after the date of this Agreement), (II) shall be included in a Registration Statement filed by the Company with the SEC pursuant to this Agreement and the Registration Rights Agreement and declared effective by
the SEC on or prior to the Additional Commitment Fee Trigger Date, registering under the Securities Act the resale by the Investor of such Additional Commitment Shares that may be issued to the Investor hereunder (it being hereby acknowledged and
agreed that (x)&nbsp;no shares of Common Stock may be issued to the Investor as Additional Commitment Shares hereunder if such shares are not included in a Registration Statement (and designated therein as Additional Commitment Shares that may be
issued to the Investor pursuant to this Agreement) that has been declared effective by the SEC on or prior to the Additional Commitment Fee Trigger Date and (y)&nbsp;to the extent any portion of the Additional Commitment Fee is not paid to the
Investor by the issuance of Additional Commitment Shares (valued in accordance with clause (I)&nbsp;above) pursuant to and in accordance with this <U>Section</U><U></U><U>&nbsp;5(e)(2)</U>, the full remaining balance of the Additional Commitment Fee
payable to the Investor hereunder shall be paid by the Company to the Investor in cash as the Additional Cash Commitment Fee (at such time and in the manner set forth herein), and (III)&nbsp;shall be received by the Investor as DWAC Shares not later
than 10:00 a.m. (New York City time) on the Business Day next following the Additional Commitment Fee Trigger Date. For the avoidance of doubt, the entire Additional Commitment Fee, shall be fully earned by the Investor as of the Additional Fee
Trigger Date, whether or not any additional Purchase Shares are purchased thereafter by the Investor under this Agreement and irrespective of any subsequent termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>Due Diligence; <FONT STYLE="white-space:nowrap">Non-Public</FONT>
Information</U>. During the term of this Agreement, the Investor shall have the right, from time to time as the Investor may reasonably deem appropriate and upon reasonable advance notice to the Company, to perform reasonable due diligence on the
Company during normal business hours. The Company and its officers and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor&#146;s due
diligence of the Company. Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of,
the transactions contemplated hereby in full compliance with applicable securities laws. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable
measures to protect the secrecy of any Confidential Information disclosed by the other party. The receiving party may disclose Confidential Information to the extent such information is required to be disclosed by law, regulation or order of a court
of competent jurisdiction or regulatory authority, provided that the receiving party shall promptly notify the disclosing party when such requirement to disclose arises, and shall cooperate with the disclosing party so as to enable the disclosing
party to: (i)&nbsp;seek an appropriate protective order; and (ii)&nbsp;make any applicable claim of confidentiality in respect of such Confidential Information; and provided, further, that the receiving party shall disclose Confidential Information
only to the extent required by the protective order or other similar order, if such an order is obtained, and, if no such order is obtained, the receiving party shall disclose only the minimum amount of such Confidential Information required to be
disclosed in order to comply with the applicable law, regulation or order. In addition, any such Confidential Information disclosed pursuant to this section shall continue to be deemed Confidential Information. Notwithstanding anything in this
Agreement to the contrary, the Company and the Investor agree that neither the Company nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or might reasonably be
considered to constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the
foregoing covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, if the Investor is
holding any Securities at the time of the disclosure of such material, <FONT STYLE="white-space:nowrap">non-</FONT> public information, the Investor shall have the right to make a public disclosure, in the form of a press release, public
advertisement or otherwise, of such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall have at least 24 hours to either publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information prior to any such disclosure by the Investor or to demonstrate to the Investor that such information does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information prior to any such disclosure by the
Investor, and the Company shall have failed to publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information or to demonstrate to the Investor that such information does not constitute material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, stockholders or agents,
for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<U>Purchase Records</U>. The Investor and the Company shall each maintain records showing the remaining Available Amount at any
given time and the dates and Purchase Amounts for each Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase or shall use such other method, reasonably satisfactory to the Investor and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<U>Taxes.</U> The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance
and delivery of any shares of Common Stock to the Investor made under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Use of Proceeds</U>. The Company will use the net proceeds from the offering as
described in the Registration Statement or the SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<U>Other Transactions</U>. The Company shall not enter into,
announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under
the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents, for so long as such
obligations of the Company are in effect pursuant to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<U>Integration</U>. From and after the date
of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its reasonable best efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security
or solicit any offers to buy any security, under circumstances that would (i)&nbsp;require registration of the offer and sale by the Company to the Investor of any of the Securities under the Securities Act, or (ii)&nbsp;cause this offering of the
Securities by the Company to the Investor to be integrated with other offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed
or designated, unless in the case of this clause (ii), stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such Principal Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<U>Limitation on Similar Transactions.</U> From and after the date of this Agreement until the later of (i)&nbsp;the <FONT
STYLE="white-space:nowrap">36-month</FONT> anniversary of the date of this Agreement and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the Commencement Date (if the Commencement has occurred), irrespective of any
earlier termination of this Agreement, the Company and its Subsidiaries shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or
any combination of units thereof) in any &#147;equity line of credit&#148;, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market</FONT></FONT> offering&#148; or other similar continuous offering in which the Company
may offer, issue or sell Common Stock or Common Stock Equivalents (or any combination of units thereof) at a future determined price, other than in connection with an Exempt Issuance. The Investor shall be entitled to seek injunctive relief against
the Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required. &#147;<U>Common
Stock Equivalents</U>&#148; means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock. &#147;<U>Exempt Issuance</U>&#148; means the issuance of (a)&nbsp;any
Securities issued or issuable to the Investor pursuant to this Agreement, and any securities, including, without limitation, Common Stock or Common Stock Equivalents (or any combination of units thereof), issued or issuable to the Investor or any
affiliate of the Investor pursuant to any other existing agreement or arrangement between the Company or any of its Subsidiaries, on the one hand, and the Investor or any of its affiliates, on the other hand, if any, (b)&nbsp;any securities issued
or issuable upon the exercise or exchange of or conversion of any shares of Common Stock or Common Stock Equivalents owned or held, directly or indirectly, by the Investor or any of its affiliates or designees at any time, (c)&nbsp;any securities,
including, without limitation, Common Stock or Common Stock Equivalents (or any combination of units thereof), issuable to the Investor or any of its affiliates or designees pursuant to any other future agreement or arrangement between the Investor
or any of its affiliates or designees, on the one hand, and the Company or any of its Subsidiaries, on the other hand, entered into after the date of this Agreement, if any, or (d)&nbsp;shares of Common Stock issued pursuant to an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market</FONT></FONT> offering&#148; under Rule 415(a)(4) under the Securities Act by the Company exclusively through one or more registered broker-dealer(s) acting as agent(s)
of the Company pursuant to a written agreement between the Company and such registered broker-dealer(s) only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFER AGENT INSTRUCTIONS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Commencement Date, the Company shall issue to the Transfer Agent, and any subsequent transfer agent, (i)&nbsp;irrevocable instructions
in the form substantially similar to those used by the Investor in substantially similar transactions (the &#147;<U>Commencement Irrevocable Transfer Agent Instructions</U>&#148;) and (ii)&nbsp;the notice of effectiveness of the Registration
Statement in the form attached as an exhibit to the Registration Rights Agreement (the &#147;<U>Notice of Effectiveness of Registration Statement</U>&#148;), in each case to issue the Commitment Shares and the Purchase Shares in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares, Initial Commitment Shares (as applicable) and Additional Commitment Shares (as applicable)
to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued only as DWAC Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no
instruction other than the Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement referred to in this <U>Section</U><U></U><U>&nbsp;6(b)</U> will be given by the Company to the Transfer Agent
with respect to the Purchase Shares or the Commitment Shares from and after Commencement, and the Purchase Shares and the Commitment Shares covered by the Registration Statement shall otherwise be freely transferable on the books and records of the
Company. If the Investor effects a sale, assignment or transfer of the Purchase Shares, the Company shall permit the transfer and shall promptly instruct the Transfer Agent (and any subsequent transfer agent) to issue DWAC Shares in such name and in
such denominations as specified by the Investor to effect such sale, transfer or assignment. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investor. Accordingly, the Company acknowledges
that the remedy at law for a breach of its obligations under this <U>Section</U><U></U><U>&nbsp;6 </U>will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this
<U>Section</U><U></U><U>&nbsp;6</U>, that the Investor shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of
showing economic loss and without any bond or other security being required. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONDITIONS TO THE COMPANY&#146;S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of the Company hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to
the satisfaction of each of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Investor shall have executed each of the Transaction Documents and
delivered the same to the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The Registration Statement covering the resale of the Purchase Shares and all of the Initial
Commitment Shares shall have been declared effective under the Securities Act by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as
of the Commencement Date as though made at that time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONDITIONS TO THE INVESTOR&#146;S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction of each of the following conditions
on or prior to the Commencement Date and, once such conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company shall have executed each of the Transaction Documents and delivered the same to the Investor; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;[Reserved]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The Common Stock shall be listed or quoted on the Principal Market, trading in the Common Stock shall not have been within the last
365&nbsp;days suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation on the Principal Market in accordance with the
applicable rules and regulations of the Principal Market, subject only to official notice of issuance; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;The Investor shall have
received the opinions and negative assurances of the Company&#146;s legal counsel dated as of the Commencement Date substantially in the forms heretofore agreed by the parties hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
of such representations and warranties is already qualified as to materiality in Section&nbsp;4 above, in which case, the portion of such representations and warranties so qualified shall be true and correct without further qualification) as of the
date hereof and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and
complied with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. The Investor shall have received a certificate, executed by
the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect substantially in the form attached hereto as <B><U>Exhibit A</U></B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;The Board of Directors of the Company shall have adopted the Signing Resolutions, which shall be in full force and effect without
any amendment or supplement thereto as of the Commencement Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;As of the Commencement Date, the Company shall have reserved
out of its authorized and unissued Common Stock, solely for the purpose of effecting purchases of Purchase Shares hereunder, 17,000,000 shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;The Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each shall have
been delivered to and acknowledged in writing by the Company and the Transfer Agent (or any successor transfer agent of the Common Stock); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;The Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in the
State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10)&nbsp;Business Days of the Commencement Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;The Company shall have delivered to the Investor a certified copy of the Certificate of Incorporation as certified by the Secretary
of State of the State of Delaware within ten (10)&nbsp;Business Days of the Commencement Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;The Company shall have delivered to the Investor a secretary&#146;s certificate
executed by the Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as <B><U>Exhibit B</U></B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;The Registration Statement covering the resale of the Purchase Shares shall have been declared effective under the Securities Act by
the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company shall have prepared and filed with the SEC, not later than one (1)&nbsp;Business Day after the effective date of the
Registration Statement, a final and complete prospectus (the preliminary form of which shall be included in the Registration Statement) and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be current and
available for the resale by the Investor of all of the Securities covered thereby. The Current Report shall have been filed with the SEC, as required pursuant to <U>Section5(a)</U>. All reports, schedules, registrations, forms, statements,
information and other documents required to have been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable time
periods prescribed for such filings under the Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;No Suspension Event has occurred, or any event which, after notice
and/or lapse of time, would become a Suspension Event has occurred; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;All federal, state and local governmental laws, rules and
regulations applicable to the transactions contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance
with the terms thereof shall have been complied with, and all consents, authorizations and orders of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state and local regulatory or
self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made,
including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state securities or &#147;Blue Sky&#148; laws or applicable rules and regulations of the Principal Market, or otherwise required by the
SEC, the Principal Market or any state securities regulators; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;No statute, regulation, order, decree, writ, ruling or injunction
shall have been enacted, entered, promulgated, threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any
of the transactions contemplated by the Transaction Documents; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;No action, suit or proceeding before any federal, state,
local or foreign arbitrator or any court or governmental authority of competent jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental authority of competent
jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking
material damages in connection with such transactions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Investor&#146;s execution and delivery of the Transaction Documents and acquiring the Securities hereunder and in
addition to all of the Company&#146;s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all of its affiliates, stockholders, members, officers, directors, employees and
direct or indirect investors and any of the foregoing Person&#146;s agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the
&#147;<U>Indemnitees</U>&#148;) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and
including reasonable attorneys&#146; fees and disbursements (the &#147;<U>Indemnified Liabilities</U>&#148;), incurred by any Indemnitee as a result of, or arising out of, or relating to (a)&nbsp;any misrepresentation or breach of any representation
or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b)&nbsp;any breach of any covenant, agreement or obligation of the Company contained in the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, or (c)&nbsp;any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery,
performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, other than, in the case of clause (c), with respect to Indemnified Liabilities which directly and primarily
result from the fraud, gross negligence or willful misconduct of an Indemnitee. The indemnity in this Section&nbsp;9 shall not apply to amounts paid in settlement of any claim if such settlement is effected without the prior written consent of the
Company, which consent shall not be unreasonably withheld, conditioned or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and
satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Payment under this indemnification shall be made within thirty (30)&nbsp;days from the date Investor makes written request for it. A certificate
containing reasonable detail as to the amount of such indemnification submitted to the Company by Investor shall be conclusive evidence, absent manifest error, of the amount due from the Company to the Investor; provided that the Investor shall
undertake to repay any amount paid to it hereunder if it is ultimately determined, by a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order of a court of competent jurisdiction, that the Investor is not entitled to be indemnified
against such Indemnified Liability by the Company pursuant to this Agreement. If any action shall be brought against any Indemnitee in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i)&nbsp;the employment thereof has been specifically authorized by the Company in writing,
(ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue
between the position of the Company and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUSPENSION EVENTS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;<U>Suspension Event</U>&#148; shall be deemed to have occurred at any time as any of the following events occurs: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;the effectiveness of a registration statement registering the resale of the Securities lapses for any reason (including, without
limitation, the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof) is unavailable to the Investor for resale of any or all of the Securities to be issued to the Investor under the
Transaction Documents, and such lapse or unavailability continues for a period of ten&nbsp;(10)&nbsp;consecutive Business Days or for more than an aggregate of thirty (30)&nbsp;Business Days in any <FONT STYLE="white-space:nowrap">365-day</FONT>
period, but excluding a lapse or unavailability where (i)&nbsp;the Company terminates a registration statement after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii)&nbsp;the Company
supersedes one registration statement with another registration statement, including (without limitation) by terminating a prior registration statement when it is effectively replaced with a new registration statement covering Securities (provided
in the case of this clause (ii)&nbsp;that all of the Securities covered by the superseded (or terminated) registration statement that have not theretofore been resold are included in the superseding (or new) registration statement); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;the suspension of the Common Stock from trading on the Principal Market for a
period of one (1)&nbsp;Business Day, provided that the Company may not direct the Investor to purchase any shares of Common Stock during any such suspension; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;the delisting of the Common Stock from The Nasdaq Capital Market (or any nationally recognized successor thereto), provided,
however, that the Common Stock is not immediately thereafter trading on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or The OTCQX Best Market or The OTCQB Venture Market
operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;the failure for any
reason by the Transfer Agent to issue (i)&nbsp;any Initial Commitment Shares to be issued to the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(i)</U> (as applicable) within two (2)&nbsp;Business Days after the date on which the Investor is
entitled to receive such Initial Commitment Shares pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(i)</U>, (ii) any Additional Commitment Shares to be issued to the Investor under <U>Section</U><U></U><U>&nbsp;5(e)(ii)</U> (as applicable) within two
(2)&nbsp;Business Days after the date on which the Investor is entitled to receive such Additional Commitment Shares pursuant to <U>Section</U><U></U><U>&nbsp;5(e)(ii)</U> hereof, or (iii)&nbsp;Purchase Shares to the Investor within two
(2)&nbsp;Business Days after the Purchase Date, Accelerated Purchase Date or Additional Accelerated Purchase Date, as applicable, on which the Investor is entitled to receive such Purchase Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;the Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if such breach
would reasonably be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach continues for a period of at least five (5)&nbsp;Business Days; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;if any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;if the Company, pursuant to or within the meaning of any Bankruptcy Law, (i)&nbsp;commences a voluntary case, (ii)&nbsp;consents to
the entry of an order for relief against it in an involuntary case, (iii)&nbsp;consents to the appointment of a Custodian of it or for all or substantially all of its property, or (iv)&nbsp;makes a general assignment for the benefit of its creditors
or is generally unable to pay its debts as the same become due; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;a court of competent jurisdiction enters an order or decree
under any Bankruptcy Law that (i)&nbsp;is for relief against the Company in an involuntary case, (ii)&nbsp;appoints a Custodian of the Company or for all or substantially all of its property, or (iii)&nbsp;orders the liquidation of the Company or
any Subsidiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;if at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;if at any time after the Commencement Date, the Exchange Cap is reached (to the extent such Exchange Cap is applicable pursuant to
<U>Section</U><U></U><U>&nbsp;2(e)</U> hereof), and the stockholder approval referred to in <U>Section</U><U></U><U>&nbsp;2(e)(i)</U> has not been obtained in accordance with the applicable rules of The Nasdaq Stock Market; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;if at any time the Investor&#146;s broker is unable to accept shares of Common Stock, including any Commitment Shares to be issued
to the Investor under <U>Section</U><U></U><U>&nbsp;5(e)</U> (as applicable) or any Purchase Shares to be issued to the Investor under this Agreement, for deposit for reasons not within the Investor&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to any other rights and remedies under applicable law and this Agreement, so long as a Suspension Event has occurred and is continuing, or if any
event which, after notice and/or lapse of time, would reasonably be expected to become a Suspension Event, has occurred and is continuing, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall not deliver to the Investor any Regular Purchase Notice, Accelerated Purchase Notice or Additional Accelerated Purchase Notice. Notwithstanding the foregoing, the foregoing sentence shall
not be deemed to apply to any notice from Nasdaq received in the future regarding the Company&#146;s failure to comply with the continuing listing standards of The Nasdaq Capital Market, and to the fact of each such failure, unless all compliance
and appeal periods for such failure have lapsed or expired; provided, however, that this sentence shall not be construed to modify any of the Suspension Events enumerated above in this <U>Section</U><U></U><U>&nbsp;10</U>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be terminated only as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a
proceeding against the Company which is not discharged within 90 days, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors (any of which
would be a Suspension Event as described in <U>Sections 10(f)</U>, <U>10(g)</U> and <U>10(h)</U> hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth below) without further action
or notice by any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;In the event that (i)&nbsp;the Company fails to file the Registration Statement with the SEC within
the period specified in Section 5(a) hereof in accordance with the terms of the Registration Rights Agreement or (ii)&nbsp;the Commencement shall not have occurred on or before September&nbsp;30, 2025, due to the failure to satisfy the conditions
set forth in <U>Sections 7</U> and <U>8</U> above with respect to the Commencement, then, in the case of clause (i)&nbsp;above, this Agreement may be terminated by the Investor at any time prior to the filing of the Registration Statement and, in
the case of clause (ii)&nbsp;above, this Agreement may be terminated by either party at the close of business on September&nbsp;30, 2025 or thereafter, in each case without liability of such party to the other party (except as set forth below);
provided, however, that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;11(b)</U> shall not be available to any party if such party is then in breach of any covenant or agreement contained in this Agreement or any
representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set forth in <U>Section</U><U></U><U>&nbsp;7(c)</U> or <U>Section</U><U></U><U>&nbsp;8(e)</U>, as applicable, could not then
be satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any
reason or for no reason by delivering notice (a &#147;<U>Company Termination</U> <U>Notice</U>&#148;) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other party under this Agreement (except
as set forth below). The Company Termination Notice shall not be effective until one (1)&nbsp;Business Day after it has been received by the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;This Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount
(which for purposes of this Section&nbsp;11(d) shall mean Fifty Million Dollars ($50,000,000)) of Purchase Shares as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any
other party under this Agreement (except as set forth below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;If, for any reason or for no reason, the full Available Amount
(which for purposes of this Section&nbsp;11(d) shall mean Fifty Million Dollars ($50,000,000)) of Purchase Shares has not been purchased in accordance with <U>Section</U><U></U><U>&nbsp;2</U> of this Agreement by the Maturity Date, this Agreement
shall automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in <U>Sections 11(a)</U> (in respect of a Suspension Event under
<U>Sections 10(f)</U>, <U>10(g)</U> and 10(h)), <U>11(d)</U> and <U>11(e)</U>, any termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;11</U> shall be effected by written notice from the Company to the Investor, or the
Investor to the Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties and covenants of the Company and the Investor contained in <U>Sections 3</U>, <U>4</U>, <U>5</U>, and <U>6</U>
hereof, the indemnification provisions set forth in <U>Section</U><U></U><U>&nbsp;9</U> hereof and the agreements and covenants set forth in <U>Sections 10</U>, <U>11</U> and <U>12</U> shall survive the execution and delivery of this Agreement and
any termination of this Agreement. No termination of this Agreement shall (i)&nbsp;affect the Company&#146;s or the Investor&#146;s rights or obligations under (A)&nbsp;this Agreement with respect to pending Regular Purchases, Accelerated Purchases
or Additional Accelerated Purchases and the Company and the Investor shall complete their respective obligations with respect to any pending Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases under this Agreement and
(B)&nbsp;the Registration Rights Agreement, which shall survive any such termination, or (ii)&nbsp;be deemed to release the Company or the Investor from any liability for intentional misrepresentation or willful breach of any of the Transaction
Documents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Governing Law; Jurisdiction; Jury Trial</U>. The corporate laws of the State of Delaware shall govern all issues concerning the
relative rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement, the Registration Rights Agreement and the other Transaction Documents shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of and venue in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter
jurisdiction, in any state court located in the city and county of New York, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve process in any manner permitted by law. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT
OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Counterparts</U>. This Agreement may be executed in two or
more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature
delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> in a &#147;.pdf&#148; format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be
considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Headings</U>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Severability</U>. If any provision of this Agreement shall be invalid or unenforceable in
any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Entire Agreement</U>. The Transaction Documents supersede all other prior oral
or written agreements between the Investor, the Company, their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments referenced herein
contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or
undertaking with respect to such matters. The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>Notices</U>. Any notices, consents, waivers or other communications required or permitted to be given under the terms of
this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt when delivered personally; (ii)&nbsp;upon receipt when sent by facsimile or email (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party); or (iii)&nbsp;one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses
and facsimile numbers and email addresses for such communications shall be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2710 Reed
Road, Suite 160</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Houston, Texas 77051</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(737) <FONT STYLE="white-space:nowrap">255-7194</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">mhedrick@plustherapeutics.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mark H. Hedrick, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sullivan&nbsp;&amp; Worcester LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas, 19th Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">660-3000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ddanovitch@sullivanlaw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">aschleicher@sullivanlaw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">David E. Danovitch, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aaron M. Schleicher, Esq.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Investor: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Lincoln Park Capital Fund, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">415 N. LaSalle Drive, Suite 700B</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chicago, IL 60654</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(312) <FONT STYLE="white-space:nowrap">822-9300</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(312) <FONT STYLE="white-space:nowrap">822-9301</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua Scheinfeld/Jonathan Cope</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Reed Smith LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">599 Lexington Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">549-0285</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">521-5450</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">amarsico@reedsmith.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthony J. Marsico, Esq.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Transfer Agent: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broadridge Corporate Issuer Solutions, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1717 Arch Street, Suite 1300</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Philadelphia, PA 19103</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(720) <FONT STYLE="white-space:nowrap">957-8195</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michael Dromgoole, Relationship Manager</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other address, email address and/or facsimile number and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent or other communication,
(B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine or email account containing the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission
or (C)&nbsp;provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii)
or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit
of the parties and their respective successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction, whether by
merger, reorganization, restructuring, or consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall not be deemed an assignment. The Investor may not assign its rights or
obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns and, except as set forth in Section&nbsp;9, is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Publicity</U>. The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall
consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of the
Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof; provided, however, that
this provision shall not apply to any portion of any Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q</FONT> that does not relate to the Investor, its purchases hereunder or any aspect of the
Transaction Documents or the transactions contemplated hereby. The Investor must be provided with a final version of any portion of such press release, SEC filing or other public disclosure relating to the Investor, its purchases hereunder or any
aspect of the Transaction Documents or the transactions contemplated hereby at least 24 hours prior to any release, filing or use by the Company thereof. The Company agrees and acknowledges that its failure to fully comply with this provision
constitutes a Material Adverse Effect. The Investor shall not make any public announcement or disclosure regarding this Agreement and the transactions contemplated hereby without the prior written consent of the Company, except as may be required by
applicable law or pursuant to the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<U>Further Assurances</U>. Each party shall do and perform, or cause to be done
and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to consummate and make effective, as soon as
reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<U>No Financial Advisor, Placement Agent, Broker or Finder</U>. The Company represents and warrants to the Investor that it has not
engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or
finder engaged by the Company in connection with the transactions contemplated hereby. The Company shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder relating to or
arising out of the transactions contemplated hereby. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys&#146; fees and out of pocket expenses) arising in
connection with any such claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<U>No Strict Construction</U>. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. In addition, each and every reference to share prices and shares of Common Stock in this Agreement shall be subject
to adjustment as provided in this Agreement for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<U>Remedies, Other Obligations, Breaches and Injunctive Relief</U>. The Investor&#146;s remedies provided in this Agreement,
including, without limitation, the Investor&#146;s remedies provided in Section&nbsp;9, shall be cumulative and in addition to all other remedies available to the Investor under this Agreement, at law or in equity (including a decree of specific
performance and/or other injunctive relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit the Investor&#146;s right to pursue actual
damages for any failure by the Company to comply with the terms of this Agreement. The parties acknowledges that a breach by any party of its obligations hereunder will cause irreparable harm to the
<FONT STYLE="white-space:nowrap">non-breaching</FONT> party and that the remedy at law for any such breach may be inadequate. The parties therefore agree that, in the event of any such breach or threatened breach, the
<FONT STYLE="white-space:nowrap">non-breaching</FONT> party shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other
security being required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<U>Enforcement Costs</U>. If: (i)&nbsp;this Agreement is placed by the Investor or the Company in the
hands of an attorney for enforcement or is enforced by the Investor or the Company through any legal proceeding; (ii)&nbsp;an attorney is retained to represent the Investor or the Company in any bankruptcy, reorganization, receivership or other
proceedings affecting creditors&#146; rights and involving a claim under this Agreement; or (iii)&nbsp;an attorney is retained to represent the Investor or the Company in any other proceedings whatsoever in connection with this Agreement, then the
party against which redress is sought under this section shall pay all reasonable costs and expenses including reasonable attorneys&#146; fees incurred in connection therewith to the party incurring such costs and expenses, as incurred in addition
to all other amounts due hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;<U>Amendment and Waiver; Failure or Indulgence Not Waiver</U>. No provision of this
Agreement may be amended or waived by the parties from and after the date that is one (1)&nbsp;Business Day immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence,
(i)&nbsp;no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto and (ii)&nbsp;no provision of this Agreement may be waived other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in a written instrument signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>** Signature Page Follows ** </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Investor and the Company have caused this Agreement to be
duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>THE COMPANY:</U></B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PLUS THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTOR:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LINCOLN PARK CAPITAL FUND, LLC</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BY: LINCOLN PARK CAPITAL, LLC</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BY: ROCKLEDGE CAPITAL CORPORATION</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBITS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Officer&#146;s Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Secretary&#146;s Certificate</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF OFFICER&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Officer&#146;s Certificate (&#147;<B>Certificate</B>&#148;) is being delivered pursuant to <U>Section</U><U></U><U>&nbsp;8(e)</U> of that
certain Purchase Agreement dated as of June&nbsp;17, 2025, (&#147;<B>Purchase Agreement</B>&#148;), by and between <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation (the &#147;<B>Company</B>&#148;), and <B>LINCOLN PARK CAPITAL FUND, LLC
</B>(the &#147;<B>Investor</B>&#148;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned, &#8195;&#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;&#8195; of the Company, hereby certifies, on behalf of the
Company and not in his individual capacity, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;I am the &#8195;&#8195;&#8195;&#8195;&#8195;of the
Company and make the statements contained in this Certificate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;The representations and warranties of the Company
contained in the Purchase Agreement are true and correct in all material respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section&nbsp;4 of the Purchase Agreement, in which
case, such representations and warranties are true and correct without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific
date, in which case such representations and warranties are true and correct as of such date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;The Company has
performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to
any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally
able to pay its debts as they become due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, I have hereunder signed my name on this &#8195; day of
&#8195;&#8195;&#8195;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned as Secretary of <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation, hereby certifies
that &#8195;&#8195;&#8195;&#8195;&#8195; is the duly elected, appointed, qualified and acting &#8195;&#8195;&#8195;&#8195;&#8195; of <B>PLUS THERAPEUTICS, INC. </B>and that the signature appearing above is his genuine signature. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Secretary</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SECRETARY&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Secretary&#146;s Certificate (&#147;Certificate&#148;) is being delivered pursuant to <U>Section</U><U></U><U>&nbsp;8(k)</U> of that
certain Purchase Agreement dated as of June 17, 2025 (&#147;Purchase Agreement&#148;), by and between <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation (the &#147;Company&#148;) and <B>LINCOLN PARK CAPITAL FUND, LLC </B>(the
&#147;Investor&#148;), pursuant to which the Company may sell to the Investor up to Fifty Million Dollars ($50,000,000) of the Company&#146;s Common Stock, $0.001 par value per share (the &#147;Common Stock&#148;). Terms used herein and not
otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned,
&#8195;&#8195;&#8195;&#8195;&#8195;, Secretary of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;I am the Secretary of the Company and make the statements contained in this Secretary&#146;s Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;Attached hereto as <U>Exhibit A</U> and <U>Exhibit B</U> are true, correct and complete copies of the Company&#146;s
Amended and Restated Bylaws (&#147;Bylaws&#148;) and Amended and Restated Certificate of Incorporation (&#147;Charter&#148;), in each case, as amended through the date hereof, and no action has been taken by the Company, its directors, officers or
stockholders, in contemplation of the filing of any further amendment relating to or affecting the Bylaws or Charter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;Attached hereto as <U>Exhibit C</U> are true, correct and complete copies of the resolutions duly adopted by the Board
of Directors of the Company on &#8195;&#8195;&#8195;&#8195;&#8195;, at which a quorum was present and acting throughout. Such resolutions have not been amended, modified or rescinded and remain in full force and effect and such resolutions are the
only resolutions adopted by the Company&#146;s Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i)&nbsp;the entering into and performance of the Purchase Agreement, the Registration Rights
Agreement and the other Transaction Documents, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares, and (ii)&nbsp;and the performance of the Company of its obligations under each of the Transaction Documents as
contemplated therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;As of the date hereof, the authorized, issued and reserved capital stock of the Company is
as set forth on <U>Exhibit D</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, I have hereunder signed my name on this &#8195; day of
&#8195;&#8195;&#8195;, 201&#8195;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[NAME]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned as &#8195;&#8195;&#8195;&#8195;&#8195; of <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation, hereby
certifies that &#8195;&#8195;&#8195;&#8195;&#8195; is the duly elected, appointed, qualified and acting Secretary of <B>PLUS THERAPEUTICS, INC.</B>, and that the signature appearing above is his genuine signature. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[NAME]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[TITLE]</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d925162dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>REGISTRATION RIGHTS AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;), dated as of June 17, 2025, by and between <B>PLUS THERAPEUTICS,
INC.</B><B>, </B>a Delaware corporation (the &#147;<U>Company</U>&#148;), and <B>LINCOLN PARK</B><B> CAPITAL FUND, LLC,</B> an Illinois limited liability company (together with it permitted assigns, the &#147;<U>Buyer</U>&#148;). Capitalized terms
used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to
time, the &#147;<U>Purchase Agreement</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to the then applicable
Available Amount (as defined in the Purchase Agreement) of Purchase Shares and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and
the rules and regulations thereunder, or any similar successor statute (collectively, the &#147;<U>Securities Act</U>&#148;), and applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyer, intending to be legally bound, hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>DEFINITIONS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;&#148;<U>Investor</U>&#148; means the Buyer, any transferee or assignee thereof to whom the Buyer assigns its rights under this
Agreement in accordance with Section&nbsp;9 and who agrees to become bound by the provisions of this Agreement, and any transferee or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement in accordance with
Section&nbsp;9 and who agrees to become bound by the provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;&#148;<U>Person</U>&#148; means any
individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership, an organization, a business, an individual, a governmental or political subdivision thereof or a governmental agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;&#148;<U>Register</U>,&#148; &#147;<U>registered</U>,&#148; and &#147;<U>registration</U>&#148; refer to a registration effected by
preparing and filing one or more Registration Statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities Act or any successor rule providing for offering securities on a continuous basis
(&#147;<U>Rule 415</U>&#148;), and the declaration or ordering of effectiveness of such Registration Statement(s) by the United States Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;&#148;<U>Registrable Securities</U>&#148; means all of the Commitment Shares (including all of the Initial Commitment Shares to be
issued to the Investor in payment of all or any part of the Initial Commitment Fee pursuant to Section&nbsp;5(e)(1) of the Purchase Agreement and all of the Additional Commitment Shares to be issued to the Investor in payment of all or any part of
the Additional Commitment Fee pursuant to Section&nbsp;5(e)(2) of the Purchase Agreement) and all of the Purchase Shares that may, from time to time, be issued or become issuable to the Investor under the Purchase Agreement (without regard to any
limitation or restriction on purchases), and any and all shares of capital stock issued or issuable with respect to the Purchase Shares, the Commitment Shares or the Purchase Agreement as a result of any stock split, stock dividend,
recapitalization, exchange or similar event or otherwise, without regard to any limitation on purchases under the Purchase Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e.&#8195;&#148;<U>Registration Statement</U>&#148; means one or more registration statements
of the Company covering only the resale of the Registrable Securities, including, for the avoidance of doubt, the Initial Registration Statement (as defined below) and any New Registration Statement (as defined below). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>REGISTRATION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;<U>Mandatory Registration.</U> The Company shall, within ten (10)&nbsp;Business Days after the date hereof, file with the SEC an
initial Registration Statement covering the maximum number of Registrable Securities as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable
Securities by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the Investor in consultation with their respective legal counsel, subject to
the aggregate number of authorized shares of the Company&#146;s Common Stock then available for issuance in its Certificate of Incorporation (the &#147;<U>Initial Registration Statement</U>&#148;). The Initial Registration Statement shall register
only the Registrable Securities. The Investor and its counsel shall have a reasonable opportunity to review and comment upon the Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus prior
to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall furnish all information reasonably requested by the Company for inclusion therein. The Company shall use commercially reasonable
efforts to have the Registration Statement and any amendment declared effective by the SEC at the earliest possible date. The Company shall use commercially reasonable efforts to keep the Registration Statement effective pursuant to Rule 415
promulgated under the Securities Act and available for the resale by the Investor of all of the Registrable Securities covered thereby at all times until the date on which the Investor shall have resold all the Registrable Securities covered thereby
and no Available Amount remains under the Purchase Agreement (the &#147;<U>Registration Period</U>&#148;). The Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;<U>Rule 424 Prospectus</U>. The Company shall, as required by applicable securities regulations, from time to time file with the SEC,
pursuant to Rule 424 promulgated under the Securities Act, the prospectus and prospectus supplements, if any, to be used in connection with sales of the Registrable Securities under the Registration Statement. The Investor and its counsel shall have
a reasonable opportunity to review and comment upon such prospectus prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable best efforts to comment upon such
prospectus within one (1)&nbsp;Business Day from the date the Investor receives the final <FONT STYLE="white-space:nowrap">pre-filing</FONT> version of such prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;<U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under the Registration Statement is
insufficient to cover all of the Registrable Securities, the Company shall amend the Registration Statement or file a new Registration Statement (a &#147;<U>New Registration Statement</U>&#148;), so as to cover all of such Registrable Securities
(subject to the limitations set forth in Section&nbsp;2(a)) as soon as practicable, but in any event not later than ten (10)&nbsp;Business Days after the necessity therefor arises, subject to any limits that may be imposed by the SEC pursuant to
Rule 415 under the Securities Act. Notwithstanding anything herein to the contrary, (I) if any Initial Commitment Shares are to be issued to the Investor by the Company as payment of all or any part of the Initial Commitment Fee to be paid to the
Investor pursuant to Section 5(e)(1) of the Purchase Agreement, all such Initial Commitment Shares to be issued by the Company to the Investor pursuant to Section 5(e)(1) of the Purchase Agreement shall be included in either the Initial Registration
Statement or a New Registration Statement filed by the Company with the SEC pursuant to this Agreement and the Purchase Agreement and declared effective by the SEC on or prior to the Initial Commitment Fee Trigger Date, which Initial Registration
Statement or New Registration Statement (as applicable) shall register under the Securities Act the resale by the Investor of all such Initial Commitment Shares to be issued by the Company to the Investor pursuant to Section 5(e)(1) of the Purchase
Agreement (it being hereby acknowledged and agreed that (i) no shares of Common Stock may be issued by the Company to the Investor as Initial Commitment Shares pursuant to Section 5(e)(1) of the Purchase Agreement if such shares of Common Stock are
not included in either the Initial Registration Statement or a New Registration Statement (and designated therein as Initial Commitment Shares that may be issued by the Company to the Investor pursuant to the Purchase Agreement) that has been
declared effective by the SEC on or prior to the Initial Commitment Fee Trigger Date; and (II) if any Additional Commitment Shares are to be issued to the Investor by the Company as payment of all or any part of the Additional Commitment Fee to be
paid to the Investor pursuant to Section 5(e)(2) of the Purchase Agreement, all such Additional Commitment Shares to be issued by the Company to the Investor pursuant to Section 5(e)(2) of the Purchase Agreement shall be included in a New
Registration Statement filed by the Company with the SEC pursuant to this Agreement and the Purchase Agreement and declared effective by the SEC on or prior to the Additional Commitment Fee Trigger Date, which New Registration Statement shall
register under the Securities Act the resale by the Investor of all such Additional Commitment Shares to be issued by the Company to the Investor pursuant to Section 5(e)(2) of the Purchase Agreement (it being hereby acknowledged and agreed that (i)
no shares of Common Stock may be issued by the Company to the Investor as Additional Commitment Shares pursuant to Section 5(e)(2) of the Purchase Agreement if such shares of Common Stock are not included in a New Registration Statement (and
designated therein as Additional Commitment Shares that may be issued by the Company to the Investor pursuant to the Purchase Agreement) that has been declared effective by the SEC on or prior to the Additional Commitment Fee Trigger Date. The
Company shall use its reasonable best efforts to cause each such amendment to the Registration Statement and each such New Registration Statement required to be filed by the Company with the SEC hereunder to become effective as soon as practicable
following the initial filing thereof by the Company with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;<U>Offering</U>. If the staff of the SEC (the &#147;<U>Staff</U>&#148;) or the SEC
seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales by the
Investor under Rule 415 at then-prevailing market prices (and not fixed prices), or if after the filing of the Initial Registration Statement with the SEC pursuant to Section&nbsp;2(a), the Company is otherwise required by the Staff or the SEC to
reduce the number of Registrable Securities included in such Initial Registration Statement, then the Company shall reduce the number of Registrable Securities to be included in such Initial Registration Statement (after consulting with the Investor
and its legal counsel as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the SEC shall so permit such Initial Registration Statement to become effective and be used as aforesaid. In the event of any
reduction in Registrable Securities included in the Initial Registration Statement (or any New Registration Statement) pursuant to this paragraph, the Company shall file one or more New Registration Statements in accordance with Section&nbsp;2(c)
until such time as all Registrable Securities have been included in Registration Statements that have been declared effective and the prospectus contained therein is available for use by the Investor. Notwithstanding any provision herein or in the
Purchase Agreement to the contrary, the Company&#146;s obligations to register Registrable Securities (and any related conditions to the Investor&#146;s obligations) shall be qualified as necessary to comport with any requirement of the SEC or the
Staff as addressed in this Section&nbsp;2(d). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>RELATED OBLIGATIONS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Registration Statement and whenever any Registrable Securities are to be registered pursuant to Section&nbsp;2 including on
any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have
the following obligations: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;The Company shall prepare and file with the SEC such amendments (including post-effective amendments)
and supplements to any Registration Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep the
Registration Statement or any New Registration Statement effective at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities
of the Company covered by the Registration Statement or any New Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the Investor as set
forth in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;The Company shall permit the Investor to review and comment upon the Registration
Statement or any New Registration Statement and all amendments and supplements thereto at least two (2)&nbsp;Business Days prior to their filing with the SEC, and not file any such document in a form to which Investor reasonably objects. The
Investor shall use its reasonable best efforts to comment upon the Registration Statement or any New Registration Statement and any amendments or supplements thereto within two (2)&nbsp;Business Days from the date the Investor receives the final
version thereof. The Company shall furnish to the Investor, without charge any correspondence from the SEC or the staff of the SEC to the Company or its representatives relating to the Registration Statement or any New Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;Upon request of the Investor, the Company shall furnish to the Investor,
(i)&nbsp;promptly after the same is prepared and filed with the SEC, at least one copy of such Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference and all
exhibits, (ii)&nbsp;upon the effectiveness of any Registration Statement, a copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably
request) and (iii)&nbsp;such other documents, including copies of any preliminary or final prospectus, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by the
Investor. For the avoidance of doubt, any filing available to the Investor via the SEC&#146;s EDGAR system shall be deemed &#147;furnished to the Investor&#148; hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;The Company shall use reasonable best efforts to (i)&nbsp;register and qualify the Registrable Securities covered by a Registration
Statement under such other securities or &#147;blue sky&#148; laws of such jurisdictions in the United States as the Investor reasonably requests, (ii)&nbsp;prepare and file in those jurisdictions, such amendments (including post-effective
amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii)&nbsp;take such other actions as may be reasonably necessary to maintain such
registrations and qualifications in effect at all times during the Registration Period, and (iv)&nbsp;take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however,
that the Company shall not be required in connection therewith or as a condition thereto to (x)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section&nbsp;3(d), (y) subject itself to
general taxation in any such jurisdiction, or (z)&nbsp;file a general consent to service of process in any such jurisdiction. The Company shall promptly notify the Investor who holds Registrable Securities of the receipt by the Company of any
notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or &#147;blue sky&#148; laws of any jurisdiction in the United States or its receipt of actual notice
of the initiation or threatening of any proceeding for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e.&#8195;As promptly as practicable after becoming aware of such
event or facts, the Company shall notify the Investor in writing of the happening of any event or existence of such facts as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of
a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare a supplement or amendment to
such Registration Statement to correct such untrue statement or omission, and deliver a copy of such supplement or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company shall also promptly
notify the Investor in writing (i)&nbsp;when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when a Registration Statement or any post-effective amendment has become effective (notification of such
effectiveness shall be delivered to the Investor by email or facsimile on the same day of such effectiveness and by overnight mail), (ii) of any request by the SEC for amendments or supplements to any Registration Statement or related prospectus or
related information, and (iii)&nbsp;of the Company&#146;s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">f.&#8195;The Company shall use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of
any Registration Statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest
possible moment and to notify the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">g.&#8195;The Company shall (i)&nbsp;cause all the Registrable Securities to be listed on
each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, or (ii)&nbsp;secure designation
and quotation of all the Registrable Securities on the Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">h.&#8195;The Company shall cooperate with the Investor to facilitate the timely issuance of the Registrable Securities to be offered pursuant
to any Registration Statement, it being agreed that such Registrable Securities shall be issued as DWAC Shares and in such denominations or amounts as the Investor may reasonably request and registered in such names as the Investor may request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i.&#8195;The Company shall at all times provide a transfer agent and registrar with respect to its Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">j.&#8195;If reasonably requested by the Investor, the Company shall (i)&nbsp;as soon as practicable after receipt of written notice from the
Investor incorporate in a prospectus supplement or post-effective amendment such information as the Investor reasonably requests should be included therein relating to the sale and distribution of Registrable Securities, including, without
limitation, information with respect to the number of Registrable Securities being sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities; (ii)&nbsp;make all required filings of such prospectus
supplement or post-effective amendment as soon as practicable upon notification of the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii)&nbsp;supplement or make amendments to any Registration Statement
or New Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">k.&#8195;The Company shall use its reasonable best efforts to cause the Registrable Securities covered by
any Registration Statement to be registered with or approved by such other governmental agencies or authorities in the United States as may be necessary to consummate the disposition of such Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">l.&#8195;Within one (1)&nbsp;Business Day after any Registration Statement which includes the Registrable Securities is declared effective by
the SEC, the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to the Investor) confirmation that such Registration Statement has been declared
effective by the SEC substantially in the form attached hereto as <U>Exhibit A</U>. Thereafter, if requested by the Buyer at any time, the Company shall require its counsel to deliver to the Buyer a written confirmation whether or not the
effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not the Registration Statement is current and available to the Buyer for sale of all of
the Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">m.&#8195;The Company shall take all other reasonable actions necessary to expedite and facilitate disposition
by the Investor of the Registrable Securities pursuant to any Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>OBLIGATIONS OF THE INVESTOR</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in connection
with any Registration Statement hereunder. The Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be
reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;The Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and
filing of any Registration Statement hereunder and any amendments and supplements thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;The Investor agrees that, upon
receipt of any notice from the Company of the happening of any event or existence of facts of the kind described in Section&nbsp;3(f) or the first sentence of Section&nbsp;3(e), the Investor will immediately discontinue disposition of Registrable
Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the Investor&#146;s receipt of the copies of a notice regarding the resolution or withdrawal of the stop order or suspension as contemplated by
Section&nbsp;3(f) or the supplemented or amended prospectus as contemplated by the first sentence of Section&nbsp;3(e). Notwithstanding anything to the contrary, the Company shall cause its transfer agent to promptly deliver shares of Common Stock
without any restrictive legend in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which an Investor has entered into a contract for sale prior to the Investor&#146;s receipt
of a notice from the Company of the happening of any event of the kind described in Section&nbsp;3(f) or the first sentence of Section&nbsp;3(e) and for which the Investor has not yet settled. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EXPENSES OF REGISTRATION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All reasonable expenses, other than sales or brokerage commissions, incurred in connection with registrations, filings or qualifications
pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>INDEMNIFICATION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each
Person, if any, who controls the Investor, the members, the directors, officers, partners, employees, agents, representatives of the Investor and each Person, if any, who controls the Investor within the meaning of the Securities Act or the
Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;) (each, an &#147;<U>Indemnified Person</U>&#148;), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable
attorneys&#146; fees, amounts paid in settlement (with the consent of the Company, such consent not to be unreasonably withheld) or reasonable expenses, joint or several, (collectively, &#147;<U>Claims</U>&#148;) incurred in investigating, preparing
or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or
not an indemnified party is or may be a party thereto (&#147;<U>Indemnified Damages</U>&#148;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out
of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact in the Registration Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made in connection with the
qualification of the offering under the securities or other &#147;blue sky&#148; laws of any jurisdiction in which Registrable Securities are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offered (&#147;<U>Blue Sky Filing</U>&#148;), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission
or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading, (iii)&nbsp;any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to the Registration
Statement or any New Registration Statement or (iv)&nbsp;any material violation by the Company of this Agreement (the matters in the foregoing clauses (i)&nbsp;through (iv) being, collectively, &#147;<U>Violations</U>&#148;). The Company shall
reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.
Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section&nbsp;6(a): (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance
upon and in conformity with information about the Investor furnished in writing to the Company by any Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement or any such
amendment thereof or supplement thereto or prospectus contained therein, if such Registration Statement, New Registration Statement or amendment thereof or supplement thereto or prospectus contained therein was timely made available by the Company
pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); (ii) with respect to any superseded prospectus, shall not inure to the benefit of any Indemnified Person from whom the Indemnified Person asserting any such Claim purchased the Registrable
Securities that are the subject thereof (or to the benefit of any Person controlling such Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as
then amended or supplemented, if such revised prospectus was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e), and the Indemnified Person was promptly advised in writing not to use the incorrect prospectus
prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice, used it; (iii)&nbsp;shall not be available to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered
the prospectus made available by the Company, if such prospectus was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); and (iv)&nbsp;shall not apply to amounts paid in settlement of any Claim if such settlement
is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and
shall survive the transfer of the Registrable Securities by the Investor pursuant to Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;In connection with the
Registration Statement or any New Registration Statement or prospectus, the Investor agrees to indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section&nbsp;6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement or any New Registration Statement, each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (collectively and together with an Indemnified
Person, an &#147;<U>Indemnified Party</U>&#148;), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or
are based upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with written information about the Investor set forth on <U>Exhibit B</U> attached hereto or updated from
time to time in writing by the Investor and furnished to the Company by the Investor expressly for use in connection with such Registration Statement or prospectus or any New Registration Statement or from the failure of the Investor to deliver or
cause to be delivered the prospectus made available by the Company, if such prospectus was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); and, subject to Section&nbsp;6(d), the Investor will reimburse any
legal or other expenses reasonably incurred by any Indemnified Party in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigating or defending any such Claim; provided, however, that the indemnity agreement contained in this Section&nbsp;6(b) and the agreement with respect to contribution contained in
Section&nbsp;7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld; provided, further, however, that the
Investor shall be liable under this Section&nbsp;6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the sale of Registrable Securities pursuant to such Registration
Statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section&nbsp;9.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;Promptly after receipt by an Indemnified Person or Indemnified Party under this Section&nbsp;6 of notice of the commencement of
any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;6,
deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be; provided, however, that an Indemnified Person or
Indemnified Party shall have the right to retain its own counsel with the fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the
Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such
proceeding. The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party
all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as to the status of
the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall
not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise which does
not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified Person of a release from all liability in respect to such claim or litigation. Following indemnification as provided for
hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section&nbsp;6,
except to the extent that the indemnifying party is prejudiced in its ability to defend such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;The indemnification
required by this Section&nbsp;6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant
to this Section&nbsp;6 that is later determined not to be entitled to such payment shall return such payment to the person making it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e.&#8195;The indemnity agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Indemnified
Party or Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be subject to pursuant to applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>CONTRIBUTION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable under Section&nbsp;6 to the fullest extent permitted by law; provided, however, that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii)&nbsp;contribution by any seller of Registrable
Securities shall be limited in amount to the net amount of proceeds received by such seller from the sale of such Registrable Securities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>REPORTS AND DISCLOSURE UNDER THE SECURITIES ACT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">With a view to making available to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or
regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration (&#147;<U>Rule 144</U>&#148;), the Company agrees, at the Company&#146;s sole expense, so long as the Investor owns
Registrable Securities, to use reasonable best efforts to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;make and keep public information available, as those terms are
understood and defined in Rule 144; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;furnish to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i)&nbsp;a written statement by
the Company that it has complied with the reporting and or disclosure provisions of Rule 144, the Securities Act and the Exchange Act, (ii)&nbsp;a copy of the most recent annual or quarterly report of the Company and such other reports and documents
so filed by the Company, and (iii)&nbsp;such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;take such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities
pursuant to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company&#146;s Transfer Agent as may be reasonably requested from time to time by the Investor and
otherwise fully cooperate with Investor and Investor&#146;s broker to effect such sale of securities pursuant to Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company
agrees that damages may be an inadequate remedy for any breach of the terms and provisions of this Section&nbsp;8 and that Investor shall, whether or not it is pursuing any remedies at law, be entitled to seek equitable relief in the form of a
preliminary or permanent injunctions, without having to post any bond or other security, upon any breach or threatened breach of any such terms or provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ASSIGNMENT OF REGISTRATION RIGHTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided,
however, that any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall not be deemed an assignment. The
Investor may not assign its rights under this Agreement without the prior written consent of the Company, other than to an affiliate of the Investor controlled by Jonathan Cope or Joshua Scheinfeld, in which case the assignee must agree in writing
to be bound by the terms and conditions of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>AMENDMENT OF REGISTRATION RIGHTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1)&nbsp;Business Day immediately
preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement may be (i)&nbsp;amended other than by a written instrument signed by both parties hereto or
(ii)&nbsp;waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such
right or remedy, shall not operate as a waiver thereof. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>MISCELLANEOUS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a.&#8195;A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the
registered owner of such Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b.&#8195;Any notices, consents, waivers or other communications required or permitted to
be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, when delivered personally; (ii)&nbsp;upon receipt, when sent by facsimile or email (provided confirmation of transmission
is mechanically or electronically generated and kept on file by the sending party); or (iii)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the
same. The addresses, email addresses and facsimile numbers for such communications shall be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2710 Reed
Road, Suite 160</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Houston, Texas 77051</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(737) <FONT STYLE="white-space:nowrap">255-7194</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">mhedrick@plustherapeutics.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mark H. Hedrick, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sullivan&nbsp;&amp; Worcester LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas, 19<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10020</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">660-3000</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ddanovitch@sullivanlaw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">aschleicher@sullivanlaw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">David E. Danovitch, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aaron M. Schleicher, Esq.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Investor: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Lincoln Park Capital Fund, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">415 N. LaSalle Drive, Suite 700B</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chicago, IL 60654</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(312) <FONT STYLE="white-space:nowrap">822-9300</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(312) <FONT STYLE="white-space:nowrap">822-9301</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua Scheinfeld/Jonathan Cope</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Reed Smith LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">599 Lexington Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">549-0285</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">521-5450</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">amarsico@reedsmith.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthony J. Marsico, Esq.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other address, email address and/or facsimile number and/or to the attention of such other Person as the
recipient party has specified by written notice given to each other party three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent, waiver or
other communication, (B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine or email account containing the time, date, recipient facsimile number or email address, as applicable, and an image of the first page of
such transmission or (C)&nbsp;provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or email, or receipt from a nationally recognized overnight delivery service in
accordance with clause (i), (ii) or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c.&#8195;The corporate laws of the State of Delaware shall govern all
issues concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York,
without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of and venue in the U.S. District Court for the Southern District of New York, or, if that court does not have subject matter jurisdiction, in any state court located in the city and
county of New York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of
this Agreement in any other jurisdiction. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT
OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d.&#8195;This Agreement and the Purchase Agreement constitute the entire agreement among the
parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings among the parties hereto, other than those set forth or referred to herein and therein. This Agreement and the
Purchase Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e.&#8195;This Agreement is intended for the benefit of the parties hereto and, subject to the requirements of Section&nbsp;9, their successors
and permitted assigns and, except as set forth in Section&nbsp;6 with respect to those Persons entitled to indemnity thereunder, is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">f.&#8195;The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">g.&#8195;This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> in a &#147;.pdf&#148; format data
file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force
and effect as if the signature were an original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">h.&#8195;Each party shall do and perform, or cause to be done and performed,
all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this
Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i.&#8195;The language used in this Agreement will be deemed to be
the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>** Signature Page Follows ** </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights Agreement to be
duly executed as of day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>THE COMPANY</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>BUYER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LINCOLN PARK CAPITAL FUND, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: LINCOLN PARK CAPITAL, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: ROCKLEDGE CAPITAL CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua Scheinfeld</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TO REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTICE OF EFFECTIVENESS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF REGISTRATION STATEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[TRANSFER AGENT] </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Plus Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are counsel to Plus Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and have represented the Company in
connection with that certain Purchase Agreement, dated as of June 17, 2025 (the &#147;<U>Purchase Agreement</U>&#148;), entered into by and between the Company and Lincoln Park Capital Fund, LLC (the &#147;<U>Buyer</U>&#148;), pursuant to which the
Company [has issued to the Buyer an aggregate of [&#9679;] shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;), and] may in the future issue to the Buyer an aggregate of [&#9679;] shares of
Common stock and issue and sell to the Buyer shares of Common Stock having an aggregate purchase price initially of up to Twenty-Five Million Dollars ($25,000,000) and, upon the purchase by the Investor of the full Twenty-Five Million Dollars
($25,000,000) of shares of Common Stock, an additional Twenty-Five Million Dollars ($25,000,000) of shares of Common Stock, for a total aggregate amount of up to Fifty Million Dollars ($50,000,000) of shares of Common Stock, in accordance with the
terms of the Purchase Agreement. In connection with the transactions contemplated by the<B> </B>Purchase Agreement, the Company has registered with the U.S. Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) the following shares of
Common Stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[[&#9679;] shares of Common Stock that have been issued to the Buyer as an initial commitment fee (the
&#147;<U>Initial Commitment Shares</U>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[&#9679;] shares of Common Stock to be been issued to the Buyer as an additional commitment fee (the
&#147;<U>Additional Commitment Shares</U>&#148; and, collectively with the Initial Commitment Shares, the &#147;<U>Commitment Shares</U>&#148;); and]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">up to [&#9679;] shares of Common Stock to be issued to the Buyer upon purchase by the Buyer from the Company
from time to time (the<B> </B>&#147;<U>Purchase Shares</U>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, the Company also
has entered into a Registration Rights Agreement, dated as of June 17, 2025, with the Buyer (the &#147;<U>Registration Rights Agreement</U>&#148;) pursuant to which the Company agreed, among other things, to register the Purchase Shares and [the
Commitment Shares][the Initial Commitment Shares]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). In connection with the Company&#146;s obligations under the
Purchase Agreement and the Registration </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Initial Registration Statement or a New Registration Statement filed with and declared effective by the SEC
on or prior to the Initial Commitment Fee Trigger Date shall include the Initial Commitment Shares, and a New Registration Statement filed with and declared effective by the SEC on or prior to the Additional Commitment Fee Trigger Date shall include
the Additional Commitment Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See FN 2. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rights Agreement, on [&#9679;], 2025, the Company filed a Registration Statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-[&#9679;])</FONT> (the &#147;<U>Registration
Statement</U>&#148;) with the SEC relating to the resale of the Purchase Shares and [the Commitment Shares][the Initial Commitment Shares]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP>by
the Buyer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the foregoing, we advise you that a member of the SEC&#146;s staff has advised us by telephone that the SEC
has entered an order declaring the Registration Statement effective under the Securities Act at [&#9679;] [A.M./P.M.] on [&#9679;], 202[&#9679;] and we have no knowledge, based solely on our review of the stop order notification website maintained
by the SEC, that any stop order suspending its effectiveness has been issued or that any proceedings for that purpose are pending before, or threatened by, the SEC. Accordingly, the Purchase Shares and [the Commitment Shares][the Initial Commitment
Shares]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> may be resold by the Buyer under the Securities Act pursuant to the Registration Statement and may be issued without any restrictive legend or stop transfer orders maintained against
them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Company Counsel]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lincoln Park Capital Fund, LLC
</P></TD></TR></TABLE><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See FN 2. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See FN 2. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TO REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information About The Investor Furnished To The Company By The Investor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expressly For Use In Connection With The Registration Statement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information With Respect to Lincoln Park Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
the date of the Purchase Agreement, Lincoln Park Capital Fund, LLC, beneficially owned 63,500 shares of our common stock. Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund,
LLC, are deemed to be beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and investment power over the shares being offered under the prospectus filed with
the SEC in connection with the transactions contemplated under the Purchase Agreement. Neither Lincoln Park Capital, LLC nor Lincoln Park Capital Fund, LLC is a registered broker-dealer or an affiliate of a registered broker-dealer. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20250617.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/20/2025 10:17:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:pstv="http://www.plustherapeutics.com/20250617"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20250617"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20250617_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20250617_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20250617_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/20/2025 10:17:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20250617_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/20/2025 10:17:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20250617.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2710 Reed Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d925162d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d925162d8k.htm">d925162d8k.htm</File>
    <File>pstv-20250617.xsd</File>
    <File>pstv-20250617_lab.xml</File>
    <File>pstv-20250617_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d925162d8k.htm": {
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20250617",
   "dts": {
    "inline": {
     "local": [
      "d925162d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "pstv-20250617.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20250617_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20250617_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-17_to_2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925162d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-17_to_2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925162d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-143665-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-143665-xbrl.zip
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M<_=1R-EL0[,\?AXI<NU8OQ2WOR2Y9A%\'IKOOQ)>?0!=CQW+"?<3EC1R(]&
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MH8S)*I- +:Z>6P9/P8IW8(F)5)A^$UIJN_'4!A8#.(YSS]JD=7-#I^T.XN\
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M_^[]/^EV.7KS_O0HQEG#^*H,5I*G+ LV7];+9 9_NTISV \\?'F=N(7*JN%
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M9:8@BV*P65A/J 4VM-<G2$&U=GENNTL^0M\M_KS\> AB=,3PAYI.5  _;2V
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M_#&CF[:!@0XK'*:P12')]Z":ZQ*CHE0E@5<D_FN6P=J!AX)(A(,A;.:X-'6
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MJ)=E#78[?./G[564DBJT@VK/Z><%J.;'%@A@7,B(MCABMO6LF'Q, :-\,*:
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M&\?#T,QPD*_(<I!ZK2J<C+43_1-L@M2 !$:S?T36;R&"0D[HI;6%NGJE8A?
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M2K+<V+^T91,V4;TE@S88NV5*?W&#A"_[R;/HLH"-VC;ID_1XT\^17ALBP._
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ML;5D!!J81S=IQR[>QM">FARKZ]Q%\V&^>->SV0>^#XRD+B0C%7Q^;.*;@4%
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MLV%D;%HY;4]DG3UD^Q(\:/7)@<>MQ_[LODN:5N$+8:)4@B0$-LRHUSB[62!
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M:(1%:;$FPF9D+VXA?AI,YVCK!,Z8Z69=QL;M40>\?UYL?0DR \<<;RZYG2B
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M15K+T3RS60>@6QA:9S_$%OJS=C&5T9MK2FNEF$>P;*7:\%.VWK54<"M*A0:
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MS22CAA,(5/_A.GJR%QWLO-DYW8E.$DQQ?@[.WO-G\'_?P__]2$_[<>\)$S/
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M49P5DR!MF6/IQ18.EDZZB0YT\*+$JG%'W6PS84AO*]NGJG(=JBH)F:&*1CR
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M!,L&"X]!A7-!-?&)+,&8B.=83 K+ #-E)N8*$D5V#+0#H/5'IO\Y%73X)JG
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MM#@Y14)KIGH"I2M.1F.XNJ W $.%16,(0^E[,5QN>Q6,2",/A\$H&9TD/BV
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M,*T'&XM/;-8825]?)DP&]L2H(#!F5F A(H :K,X_<B6@%K;7ZBGD^6H#]UY
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MLBC".)"(B<9:G<>A9 :1OY"2V@AQ#A$QJ,G0B"DL6B)< ( +((0!S,O&/,!
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M_'R\NF)><?R^UZ<^?.P>'.,3!]!LYZ#?H5^;%QUW/W[ZT#GN[O,045M;8N8
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M#'H'>QMU<KLK3K:WMQH787L9B_! )G[W\HV=W9DU'ZW5'E=#@3W!B+K[Z'N
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MP"+]:!R[I*5+2A/WD-#&UJL9&LB#.XKBA.%G=.F1E.(&^YR9!2\^.^?'>=H
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MF4C3.R7_K35ZW#O^0*W^R2)+SV=KNT96'>Y_,1^^/_[XX>W_ U!+ P04
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MQGG!\4\:'ZJ\.!NYNN*V\?.3/(F"]()^'403Q"YP4$CM&T[WWSD\(K1?2\V
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M<7ZOGO77CY[UFWG65W8 5159]'2-1:/I7<.M,US7EHYYJFA!DVA5>='VD 5
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M=#RW5: J1)/&)I^B@_&-,,:-+>2*QU=8W**N7K<$X]87/]ZY<R-75PK@DM/
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MSSCU4>"(D=0-)=;-/&$58"_CVCJ,;.9?,$#^VI.B;@JX[\F8&MMP66WJH(H
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M%F0ZE5U\&87 HH$&G%[U].ZQQV%8F:]\OG&VX>TC+!AW:"_.DTS7WCB#/;Y
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M,\D&I;(J>&<G;'^RZLS2FRX6_Q&%=E,BW!\6R7;"N"W05 WE>R/K:0U9RQH
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M04MCFUB*5$DJB?]^AY3DR$[LNDG1P$!HSIR9,U?ZY.U=)>$&C15:C:,L22-
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M7@Q>3J\GERO3OAW&D:6\R\%X_N9P:X,_&RY!+&WY4+;M47\<:/UT\-[/-6F
M/WR>7/SXG5@]%,SQ.ZUTM6S)GNFB\6]2__^=*M\KHKB\H XS5: 7@: 794+J
MW_927Y'MZ99(O^I$:.,L]7_THZ^W,#QR54)K#@;V3MBFD4W[C<7R7W4:S@67
M12-7R>_ G<8NX&;9]D?>,]N.ZV[[PO7CS#;GN;L9SGU[U>X=^OH_4$L#!!0
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MMUM:+7<64X8"3)<#_;24_PYB]A"(Y]GL]&'QM0C5I?>::TO1G364O=;TI<Q
M?#W+DCC.$"WQ;KFZL[!B-V:$C>F$*'KV!I3/NNIR._1J.;FS>C(1V.QV'*^3
M*3_Y=K<GJBZA/:,6CVOK(_<)B+ENQZ^"+]5"CQ4I9F=N/SD2HKKH7K5M0?X/
MBR,WP4%J!OJ V0B[.6->S+9.?>0?4$L! A0#%     @ #(+46J)>G>KU'
MT[0   X              ( !     &0Y,C4Q-C)D.&LN:'1M4$L! A0#%
M  @ #(+46M&,B4PHK0  )ZX# !$              ( !(1T  &0Y,C4Q-C)D
M97@Q,#$N:'1M4$L! A0#%     @ #(+46M)^GA-40@  \&8! !$
M     ( !>,H  &0Y,C4Q-C)D97@Q,#(N:'1M4$L! A0#%     @ #(+46N $
M/4]& P  90L  !$              ( !^PP! '!S='8M,C R-3 V,3<N>'-D
M4$L! A0#%     @ #(+46G3]R/J!!@  ND8  !4              ( !<! !
M '!S='8M,C R-3 V,3=?;&%B+GAM;%!+ 0(4 Q0    (  R"U%I0"=69S@0
M % L   5              "  207 0!P<W1V+3(P,C4P-C$W7W!R92YX;6Q0
52P4&      8 !@!_ 0  )1P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d925162d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20250617.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-17_to_2025-06-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-06-17_to_2025-06-17"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-353">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-17_to_2025-06-17"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-364">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-365">2025-06-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-366">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-367">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-368">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-369">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-370">2710 Reed Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-371">Suite 160</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-372">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-373">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-374">77051</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-375">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-376">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-377">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-378">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-379">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-380">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-381">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-382">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-383">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
